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Abstract  
Breast cancer is highly prevalent in the United States with an estimated 260,000 
women diagnosed with invasive breast cancer in 2018 alone. There is a growing need to 
identify the molecular drivers of metastatic breast cancer as the molecular mechanisms 
responsible for the transition from normal mammary epithelial cells to aggressive cancer 
cells remain poorly understood. Understanding this transition may reveal a therapeutic 
target for aggressive breast cancer. Small, noncoding RNAs (ncRNA), such as microR-
NAs (miRNAs), have recently been discovered to promote initiation, progression, and 
metastasis of breast cancer. Similar in size to miRNAs, tRNA-derived small RNAs (tsR-
NAs) are a novel class of small ncRNA whose expression may differentiate between can-
cer types and cancer cell lines. TsRNAs are created during the maturation process of pri-
mary tRNA transcripts, where the 3-prime end of the tRNA is cleaved by RNaseZ, result-
ing in a 16-48 nucleotide long strand of RNA. Although similar in size to miRNA, the 
functions of tsRNA are largely unknown. Previously identified two tsRNA, ts-2 and 
ts-112, that are expressed at 10-fold higher levels in the MCF10CA1a aggressive breast 
cancer cell line than the normal-like MCF10A mammary epithelial cell line. Further, ts-2 
and ts-112 are detected at similarly high levels in female human embryonic cells, display-
ing oncofetal expression.  
For these reasons we hypothesize that ts-2 and ts-112 promote breast cancer char-
acteristics. Custom inhibitors of ts-2 and ts-112 were transfected into the aggressive 
breast cancer cell line MCF10CA1a in vitro. The following phenotypic assays were con-
ducted to determine the function of ts-2 and ts-112 in the MCF10CA1a cell line: prolifer-
ation, cell cycle, and wound healing. Following transfection of ts-2 inhibitors, in the pro-
liferation assay showed a 15-20% reduction in growth of aggressive cancer cells. Ts-2 
inhibition also saw an increase in population doubling time of 7% from 12 to 14 hours. 
These results suggest that ts-2 may play a role in cell cycle progression.  
Following ts-112 inhibition in the aggressive MCF10CA1a breast cancer cell line, 
cell cycle analysis revealed a statistically significant decrease in the number of cells in 
G1 phase and an increase in S phase. Using a candidate approach we analyzed the effect 
of ts-2 and ts-112 inhibition on G1/S phase and S/G2 phase checkpoint markers by qPCR. 
The inhibition of these tsRNA showed no effect on the chosen genes. Our data are in 
support for ts-2 and ts-112 having a role in aggressive breast cancer and may be tumor 
promoting In on-going studies, the capacity of tsRNAs to act as predictive biomarkers of 
long-term breast cancer risk is being evaluated in serum collected from women at elevat-
ed risk. Analyzing ts-2 and ts-112 biological consequences following inhibition furthers 
our understanding of the molecular mechanisms that are responsible for aggressive breast 
cancer. Continued study of tsRNA function could produce a model of their role in aggres-
sive breast cancer and thus metastasis. Understanding tsRNA function in metastatic breast 
cancer in turn could lead to their use as a possible biomarker or therapeutic target. 
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      CHAPTER 1: Introduction To Breast Cancer 
1.1 What is Cancer 
The two leading causes of death in the United States are heart disease and cancer. 
In 2019, it is estimated that more than one and a half million new cases of cancer will be 
diagnosed in the United States [1]. Globally, cancer related deaths are predicted to in-
crease from 10 to 15 million by the year 2020 [2]. Cancer is defined as an abnormal 
growth of cells that originate from a normal cell that has acquired mutations that allow 
the cell to evade normal apoptotic signaling and proliferate indefinitely [3]. Mutations 
arise when there is an alteration in a cell’s DNA that is not repaired by normal cellular 
repair mechanisms. These alterations include deletions, insertions, duplications, re-
arrangements or point mutation in a single nucleotide or base pair in the deoxyribonucleic 
acid (DNA) [4]. 
The previously mentioned mutations can either be beneficial or detrimental to the 
wellbeing of the species they occur in. Mutations are necessary to the population because 
they encourage advantageous changes in response to environmental stimulus to adapt and 
create further diversity in future generations. Although, in some cases, these mutations 
can be detrimental to the organism by resulting in an uncontrolled growth [4]. These 
growths can take the form of a solid tumor or, in the case of leukemia, the uncontrolled 
synthesis of abnormal white blood cells [5]. A solid tumor can be benign or malignant. A 
benign tumor is a non-cancerous growth that does not invade into the surrounding tissue. 
A malignant tumor is able to invade local tissues while simultaneously stealing nutrients 
from the surrounding tissues [4]. Cancerous tumors are able to form in any type of cell in 
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the body. 90% of all human cancers occur in the rapidly dividing epithelial cells resulting 
in malignant carcinomas [6].  
Cancer cells that evade the immune response make up the contents of the primary 
tumor while cancer cells that are incapable of evading the immune response are eliminat-
ed. The surviving cancer cells continue to selectively proliferate accruing mutations such 
as the ability to overcome cell cycle checkpoint machinery. The edited cancer cells, due 
to the acquisition of mutations that allow them to proliferate indefinitely, subdue apoptot-
ic signaling, evade defense mechanisms and overcome checkpoint machinery ultimately 
become immortal [4]. 
Immortal cancer cells within the primary tumor continue to undergo cell divisions 
and accrue mutations. In some cases, cancer cells undergo epithelial to mesenchymal 
transition (EMT) gaining the capacity to enter and move through the vascular or lymphat-
ic systems to a secondary site in a process called metastasis. Once the cancer cells have 
intravastated the vascular system further acquired mutations allow cancer cells to undergo 
mesenchymal-to-epithelial transition (MET) to extravasate the vascular and invade sec-




 1.2 Clinical Aspects of Breast Cancer  
Breast cancer is the second most commonly diagnosed cancer in women follow-
ing skin cancer. In 2019, it is estimated that there will be 260,000 newly diagnosed cases 
of invasive breast cancer in the United States and 42,260 breast cancer-related deaths [1]. 
In the United States one in eight women (12.38%) are diagnosed with breast cancer [6].   
The stages of cancer range from stage 0 to stage IV. In order to stage a tumor 
there are three criterion that a physician takes into account: the size of the tumor (T), tu-
mor presence in the lymphatic system as nodules (N) and metastasis (M). This process of 
Figure 1.1:  Cancer cells result from the acquisition of mutations. These mutations 
are beneficial to the cell and change its epigenetic makeup. Cancer cells continue to 
accrue new mutations and characteristics that allow the cells to rapidly proliferate and 
survive. Once formed, a group of proliferative tumor cells are called a primary tumor. 
Primary tumor cells can then acquire the ability to continue to proliferate, resist cell 
death, and invade local tissue. In some cases cancer cells acquire the ability to be-
come metastatic through a process called epithelial-to-mesenchymal transition, allow-
ing cancer cells to migrate. Metastatic cells are able to move through the blood or 
lymph system to a secondary site where they undergo mesenchymal-to-epithelial 
transition in order to create secondary tumors [5].
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Acquisition of Cancer Mutations 
staging is known as “TNM staging” created by the American Joint Committee on Cancer. 
[7].  
The varying degree of aggressiveness or presence of each characteristic defines 
each increasing stage of breast cancer. Associating a number or staging of a cancer is im-
portant for treatment and to create a standardized description of each persons unique can-
cer makeup [7].  
The first stage of breast cancer is stage 0 or carcinoma in situ. Carcinoma in situ 
breast cancer cells are only present in the initial tumor site and have not invaded locally 
or into surrounding tissues. There are two variations of carcinomas in situ in breast can-
cer, the first being ductal carcinoma in situ (DCIS) and the second lobular carcinoma in 
situ (LCIS) [8]. In DCIS, breast cancer cells originate in the ductal system while in LCIS 
breast cancer cells originate in the lobules or milk producing glands of the breast. Those 
who are diagnosed with LCIS have increased risk of breast cancer becoming invasive 
compared to those who have DCIS [8].  
Stage I breast cancer contains two substages: stage IA and stage IB. In stage IA 
the primary tumor is no larger than 20mm and is not present in the lymphatic system. 
Stage IB is defined by the presence of metastasis at equal or less than 20mm in the sur-
rounding lymph nodes. A primary tumor in this stage may or may not be detectable. 
Breast cancer can also be diagnosed as stage IB if the primary tumor is less than or equal 
to 20mm and there is metastasis to the surrounding lymph nodes. Stage IA and IB have 
no evidence of distant metastasis [9]. 
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Stage IIA breast cancer is staged when there is a primary tumor that is less than 
50mm in diameter without metastasis to the lymph. Stage IIA may be diagnosed for tu-
mors that are greater than 20mm but less than 50mm in diameter with metastasis to the 
neighboring lymph. Stage IIB will be given to those breast cancers that have a primary 
tumor larger than 20mm but less than 50mm in diameter with metastasizes to the ipsilat-
eral lymph nodes. Neither stage IIA or IIB have distant metastasis [9]. 
Stage III breast cancer has three subtypes: IIIA, IIIB and IIIC. In order to be 
staged as stage IIIA either a primary, secondary or tertiary tumor must be present that is 
between the sizes of 20mm and 50mm. The tumors of stage IIIA must have metastasis to 
local lymph nodes that cause clinical matting where the tumor is anchored to the nodes 
and the underlying structures. A tumor can be considered stage IIIA if a tertiary tumor is 
present that is larger than 50mm but lacks clinical matting of the lymph nodes. Breast 
cancer that is staged IIIB possesses four separate tumors that can have either have one or 
two nodules in the lymphatic system that cause clinical matting. Stage IIIC does not pos-
sess a tumor size requirement although this stage must have increased metastasis to local 
lymph nodes with clinical matting compared to previous stages. Stage III breast cancer 
does not metastasize to distant tissues or organs [9]. Stages I-III are considered invasive 
to auxiliary lymph nodes but not distally metastatic (9). 
The most acute stage of breast cancer is stage IV or metastatic breast cancer. In 
this stage of breast cancer there can be any number of tumors and nodules in the lymphat-
ic system that are not dependent on location. In order for the tumor to be considered a 
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distal metastasis it must be larger than 0.2mm. Distal metastases are most commonly 
found in the bone, liver and lungs  [9].  
Breast cancer is unique because its staging is also dependent on the cancer's hor-
mone receptor status. There are three important hormonal receptors associated with breast 
cancer: epidermal growth factor (EGFR), estrogen and progesterone receptors [10]. With-
in the EGFR pathway of receptors is the HER family of receptors. The HER family con-
tains four subtypes: HER1, HER2, HER3 and HER4. Of the four subtypes HER2 is most 
studied and associated with breast cancer [11]. For each of these receptors except HER2, 
a ligand binds to the receptor causing various downstream effects [10]. A ligand is a mol-
ecule that binds to a receptor and initiates a downstream cellular pathway [12]. The lig-
and for estrogen receptors is estrogen and the ligand for progesterone receptors is proges-
terone [10].  
The HER2 protein does not rely on direct ligand binding to be activated. HER2 
instead forms heterodimers with HER1/3/4 proteins, activating downstream mechanisms 
leading to cell proliferation and survival. When HER2 is overexpressed, cells may ignore 
normal apoptotic signaling and proliferate indefinitely [11]. HER2 upregulation is found 
in 20-30% of all diagnosed cases of invasive breast cancer (stage I-IV) [11].  
Estrogen receptor positive breast cancer is the most commonly diagnosed hor-
monal variant of breast cancer with 70% of breast cancers being estrogen dependent [13]. 
The activation of estrogen receptors are connected to biological functions that are associ-
ated with reproductive and non-reproductive processes. In the mammary glands, they are 
responsible for the growth, differentiation and function of the gland [14]. When estrogen 
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receptors are overexpressed on the cell membrane and bound to their ligand, estrogen, the 
estrogen receptor is internalized and transported into the nucleus where it binds to estro-
gen response elements on the DNA that cause the transcription of downstream mitogenic 
effects such as increased proliferation and cell growth in breast tissue [15]. 
Progesterone, the final hormone in breast cancer, is biologically important for the 
normal development of the mammary tissue during puberty [16]. 70% of all diagnosed 
breast cancer cases are estrogen and progesterone receptor positive although few mam-
mary cells contain estrogen or progesterone receptors normally [16]. The activation of 
progesterone receptors in breast cancer cells by the progesterone ligand results in the ini-
tiation of signal transduction pathways that induce proliferation  [17].  
A fourth subtype of breast cancer is triple negative breast cancer where tumor 
cells do not express HER2 protein, estrogen or progesterone receptors [18]. Triple nega-
tive breast cancer is not treated as easily as breast cancers which have hormone receptors 
due to their lack of mutagenic hormonal receptors. In breast cancers that are hormone re-
ceptor positive, targeted therapies are able to inhibit the specific receptors responsible for 
cell proliferation. Triple negative breast cancer treatment strategies are unable to utilize 
these targeted therapies leading to increased relapse and death rates thus making them a 
more advanced stage [19]. 
Prognosis  
Breast cancer prognosis is determined by the stage, tumor size, tumor type, recep-
tor status and lymphatic or vascular invasion for each individual diagnosis [20]. Personal 
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factors also play a role in determining the prognosis, such as the individuals race, age, 
body mass index and comorbidity [21]. A patient’s prognosis is based on population-
based studies that assess the amount of time one is disease free following remission and 
the total survival rate after five years [21]. 
The survival rate of cancer is the length of time someone can anticipate living fol-
lowing diagnosis. Survival rate is generated out of 100%  and representative of every100 
diagnoses [20]. The survival rates of all types of breast cancers following diagnoses are: 
5 years; 89%, 10 years; 83% and 15 years; 78% [22]. The 5 year survival rate of stage I 
invasive breast cancer is 90% and those who have stage II/III breast cancer with metasta-
sis to the lymph nodes have a 5 year survival rate of 85%. There is a drop in the 5 year 
survival rate of metastatic breast cancer (stage IV) compared to previous survival rates of 
only 20% [23]. These statistics suggest that metastatic breast cancer (stage IV) is in need 
of continued research in order to further our understanding of more aggressive breast 
cancers to create improved treatments and biomarkers.  
Symptoms 
 Initial signs of breast cancer include tissue abnormalities in the breast or the sur-
rounding tissue such as a palpable lump, thickening or swelling of the breast and dim-
pling of the skin. Stage 0 (DCIS/LCIS) may not show symptoms because the primary tu-
mor’s size is too small to create physical abnormalities [24]. The most common symptom 
through out all stages of breast cancer is pain [25].  Koo et al., (2017) reported that there 
are a total of 56 documented symptoms of breast cancer.  
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 Metastatic breast cancer (stage IV), presents differently than earlier stages (stages 
0-III) of breast cancer because the primary tumor has metastasized to a distal location be-
sides the local lymph nodes [26]. The most common sites for distal metastasis are to the 
bone, lungs, brain and liver. The symptoms of stage IV metastatic breast cancer have in-
creased severity compared to earlier stages because they affect these secondary sites 
(stages 0-III) and other organs. The symptoms of stage IV breast cancer may include, de-
pending on the system affected: jaundice, seizures, loss of balance, difficulty breathing, 
confusion or chronic bone pain [24]. 
Current Treatments  
 Breast cancer is treated through a combination of surgical intervention, chemo-
therapy, immunotherapy, hormone therapy and radiation therapy. Two of the biggest de-
terminants of treatment is the stage and receptor status of each individuals breast cancer. 
As previously stated, breast cancer is associated with three hormone receptors, HER2 
protein, estrogen and progesterone receptors [27].  
 Breast cancer stages I-III have a good prognosis following treatment. The first 
consideration of treatment for early stages of breast cancer is surgical intervention by re-
section of the lump or full mastectomy [28]. After removal of the tumor, women undergo 
radiation to assure that all cancer cells have been eradicated and to alleviate the risk of 
relapse [29]. Radiation treatment uses X-rays to cause DNA damage in the cancer cells 
leading to cell or tumor death [30]. Both early stages and metastatic breast cancer benefit 
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from hormone inhibiting therapies if they are receptor positive. These targeted therapies 
work by blocking the hormone receptor (estrogen or progesterone) [31].  
 80% of all diagnosed cases of breast cancer are estrogen receptor positive [18]. 
The first line treatment of estrogen receptor positive breast cancer is Tamoxifen. Tamox-
ifen is part of a class of drugs selective estrogen receptor modulators (SERM). Estrogen 
receptors are found in other organs and tissues. SERMS are selective because they are 
able to competitively inhibit only the estrogen receptors located in the breast tissue pre-
venting the continuation of downstream mitogenic pathways [31]. Tamoxifen can be giv-
en either before or after surgical intervention and can be taken for up to five years [31].  
 The first line of treatment for HER2 positive breast cancer is the monoclonal anti-
body Trastuzumab (Herceptin) [32]. The mechanism of action of Trastuzumab begins by 
binding to  HER2, causing it to internalize and degrade, reducing the mitogenic response 
of HER2 upregulation because HER2 is no longer present to heterodimerize [12].  
 Triple negative breast cancer does not express HER2, estrogen or progesterone 
receptors on the surface of the tumor and therefor has no available targeted therapies and 
consequently a poor prognosis [33]. Treatment of triple negative breast cancer consists of 
chemo- and radiation therapy [33]. Early stages of breast cancer that utilize hormone re-
ceptor targeted therapies also benefit from general treatments like chemo- and radiation 
therapy [33]. 
 Women who are diagnosed with metastatic breast cancer (stage IV) are treated 
with a combination of chemotherapy, surgery, radiation and, if applicable, hormone ther-
apy. Stage IV breast cancer requires more aggressive treatment than those diagnosed with 
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earlier stages of breast cancer because metastases are present in multiple tissues and or-
gans in the body. Stage IV breast cancer is considered by some physicians untreatable 
[34]. This belief is supported by the 20% five year survival rate of metastatic breast can-
cer (stage IV). The lack of treatment and low survival rate reveals that there is a critical 
need for further research into the basic biological mechanisms of metastatic breast cancer 
in order to develop novel treatment strategies, targeted therapeutics and possible bio-
markers [34]. 
1.3 Hallmarks of Breast Cancer 
Mutations in DNA allow cancer cells to overcome the molecular mechanisms respon-
sible for normal tissue homeostasis that prevent the creation of tumors. It is important to 
characterize these mutations to differentiate between cancer types and to understand the 
underlying biology for correct treatment. These defined characteristics of cancer are 
known as the ten hallmarks of cancer. The ten hallmarks are: evading growth suppressors, 
avoiding immune destruction, enabling replicative immortality, tumor-promoting in-
flammation, activating invasion and metastasis, inducing angiogenesis, genome instabili-
ty and mutation, resisting cell death, deregulating cellular energetics and sustaining pro-
liferative signaling. Every type of cancer is unique in which of the hallmarks it will de-
velop based on the mutations it acquires and the stimulus from the environment (Figure 
1.2) [35].  
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 All cancer cells have the ability to acquire any of the characteristics mentioned above 
in order to survive. However, they do not need to acquire all of these qualities in order to 
sustain themselves. Breast cancer is associated with sustaining proliferative signaling, 
activating invasion, metastasis, evading immune destruction, deregulating cellular ener-
getics, genome instability, and mutations in the genetics [36]. Of these, the most relevant 
hallmarks for this thesis are sustained proliferation, resisting cell death and metastasis. 
Each hallmark will be discussed in further detail in subsequent sections. 
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Figure 1.2 The ten hallmarks of cancer represent the characteristics acquired by can-
cer cells in order to survive against the body’s natural defense system. Image modified 
from source [34].
Ten Hallmarks Of Cancer
Enabling replicative immortality 
 Breast cancer cells may acquire the hallmark of cancer to proliferate indefinitely. 
In order to gain the ability to proliferate indefinitely, breast cancer cells must overcome 
mechanisms that prevent normal mammary epithelial cells from excessive growth. In-
creased proliferation in breast cancer cells is linked to decreased survival and poor prog-
nosis [37]. 
 In eukaryotic cells there are four phases of the cell cycle: G1 (gap 1), S phase 
(synthesis phase), G2 (gap 2) and M phase (mitosis) [38]. The gap phases are where the 
cell grows larger to accommodate two sets of organelles and DNA, integrate growth sig-
nals, organize the replicated the genome and prepare for chromosome segregation [39]. 
G1, S, and G2 phase are known as interphase or the time spent in between cell divisions 
or mitosis [40].  
 Cells that are not actively replicating are metabolically active, functional and qui-
escent, in the G0 phase where the cell remains until it returns into the cell cycle. In order 
to exit the G0 phase a cell must receive signals, intra- or extracellular, to divide again and 
have sufficient nutrients for division [38].   
 The duration and initiation of each phase of the cell cycle are regulated by pro-
teins called cyclins that activate the catalytic component, cyclin-dependent kinases 
(CDKs) (52). The cyclins are synthesized and degraded throughout the phases and transi-
tions of the cell cycle (G1/S/G2/M). The cell’s ability to pass into the next phase of the 
cell cycle is dependent on the presence or absence of cyclins which activate CDKs. The 
four cyclins that regulate CDK activation through the cell cycle are: D, E, A and B (52).  
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 The first phase of interphase or the phases between mitotic divisions is G1. Dur-
ing G1, the cell prepares for DNA replication in S phase and the first cyclin, cyclin D, is 
synthesized indicating the beginning of the cell cycle [40].  CDK 4/6 is activated when 
bound to rising levels of cyclin D(53). Once CDK 4/6 are activated by phosphorylation of 
cyclin D, CDK4/6 phosphorylate the retinoblastoma (RB) protein during G1 which then 
activates the E2F transcription factor. E2F binds to DNA causing the transcription of 
mRNA and translation of enzymes and proteins that allow the cell to pass through the G1/
S phase checkpoint (52). Once the cell has passed through the G1/S phase checkpoint, 
cyclin D is quickly degraded and thus unable to phosphorylate CDK 4/6 (54). In order to 
enter S phase, cells must be the appropriate size, proper nutrients and lack of mutations in 
the DNA [38]. If the cell does not have proper nutrients, growth signals and DNA in-
tegrity, the cell will return to G0 where it will continue to be metabolically active but 
with a decreased rate of protein synthesis [38].  
 In response to the synthesis of cyclin D, cyclin E is produced partway through G1 
phase and degraded midway through S phase. In order to become active, cyclin E must be 
bound to CDK2 (55). The activation of CDK2 by cyclin E is responsible for the replica-
tion of DNA and organelles during S phase (54). 
 Cyclin A is synthesized during the G1/S phase checkpoint in response to the acti-
vation of E2F and is created through out S phase where its expression peaks during G2 
phase. The catalytic component, CDK2, when bound to cyclin A is activated and able to 
phosphorylate downstream proteins for the completion of cell cycle. The activation of 
CDK2 by cyclin A is responsible for the completion of the S/G2 transition and G2/M 
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phase checkpoint after which cyclin A is quickly degraded and CDK2 is then no longer 
able to phosphorylate downstream proteins (55).  
 During G2 the cell prepares for the final phase of the cell cycle, M phase. Before 
the cell can enter M phase it must pass the G2/M checkpoint. At this checkpoint the DNA 
must have completely replicated during S phase without any mutations or damage. If the 
integrity of the DNA is compromised the cell will not pass into M phase, instead the cell 
will undergo cell cycle arrest where it will  
either begin DNA repair or apoptosis [41]. 
 M phase ends interphase and is signified by the condensation of the chromosomes 
and the presence of cyclin B [42]. Within M phase there are multiple checkpoints and 
subphases to ensure that the cell divides correctly and, importantly, to assure that the 
chromosomes are aligned on a spindle correctly for proper distribution to each daughter 
cell [39]. During the subphases of M phase the cell undergoes nuclear and cytoplasmic 
division [41]. The catalytic component, CDK1 is activated when bound to Cyclin B. Cy-
clin B and CDK1 are responsible for division of the cytoplasm during cytokinesis. Cy-
tokinesis is where the cytoplasm of the cell divides into two daughter cells and marks the 
end of the replication cycle (54). 
 Following M phase the cell will return to either G0 or G1. In order for the cell to 
pass through the M/G0/G1 transition during cell cycle, the chromosomes must be stable 
and have appropriately segregated during the substages of mitosis [39]. If a cell’s chro-
mosomes did not correctly duplicate or acquired mutations, the cell will undergo cell cy-
cle arrest. During cell cycle arrest the cell may undergo DNA repair or tumor protein 53 
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(TP53) mediated apoptosis. If the cell cycle is accurately completed the cell will enter a 
quiescent state in G0 until stimulated to reenter the cell cycle [43]. 
 Tp53 is a tumor suppressor gene that increases as levels of DNA damage increase. 
Cancer cells that have a mutation in the TP53 (p53) are able to overcome the G1/S and 
G2/M checkpoints that would typically cause a cell to undergo apoptosis as a result of 
DNA damage. When a cell experiences an increase in DNA damage the cell synthesizes 
two protein kinases that are part of the phosphatidyl-inositol 3-kinase (PI3-kinase) fami-
ly: ataxia telangiectasia and RAD3 (ATR) and ataxia telangiectasia mutated (ATM) [43]. 
Once synthesized, ATR is activated by checkpoint kinase 1 (CHK1) and ATM is activated 
by (CHK2), both of which can then phosphorylate p53 which is bound to Mdm2 [43]. 
When active, ATM or ATR phosphorylates p53 which causes the release of bound Mdm2 
increasing levels of free stable p53. Stabilized p53 is then able to act as a transcription 
factor on p53 DNA response elements.The p53 DNA response elements inhibit the cell’s 
passage through G1/S and G2/M phase checkpoints by initiating mechanisms that either 
cause the cell to undergo DNA repair mechanisms or apoptotic mechanisms [44].  
 One of the key regulators of the cell cycle checkpoints transcribed by p53 re-
sponse element is CDKN1A (p21) [45]. The synthesis of CKDN1A (p21) results in the 
inhibition of G1/S and G2/M phases when bound to phosphorylated RB tumor suppressor 
protein. When CDKN1A (p21) is bound to phosphorylated RB it inhibits the binding of 
RB with E2F. E2F is an important transcription factor that signals for the cell to synthe-
size cyclin D, the initiator of the synthesis of cyclins during the cell cycle [46]. When RB 
is mutated in cancers it can no longer inhibit E2F causing the cell to continue creating 
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cyclin D thus leading to indefinite  proliferation. CDKN1A (P21) production inhibits 
cdk2 that binds to and activates both cyclin A and E. Both cyclins are responsible for the 
cell passing through the G1 and S phases. When there is a mutation in the Tp53 gene it 
can no longer synthesize CDKN1A (p21). When CDKN1A (p21) is not synthesized the 
cell constituently creates cyclin A and E allowing the cell to continuously pass through 
these phases of the cell cycle [46].  
 Serine and arginine-rich splicing factor 3 (SRSF3) synthesis is necessary for the 
cell to pass through the G1/S checkpoint. In the absence of SRSF3, cells are unable to 
pass through the G1/S phase checkpoint and instead the cell will undergo cell cycle arrest 
[47]. One study found that the knockdown of SRSF3 was linked to a decrease in cyclin 
D, the initiating cyclin of the cell cycle [47]. In other hormonal cancers, such as ovarian 
cancer, SRSF3 has been found to be overexpresesd and associated with BRCA1 suppres-
sion, a commonly mutated tumor suppressor gene found in breast cancer [48]. 
Resisting Cell Death  
 One of the hallmarks of cancer is a cancer cells ability to overcome the natural 
mechanisms that lead to cell death. There are two common ways that a cell dies, necrosis, 
or the most common, apoptosis. When a cell undergoes apoptosis, it experiences chro-
matin condensation, reduction in cell size and degradation of the nucleus. Apoptosis is a 
normal part of cellular function and occurs when there is substantial DNA or cellular 
damage. Apoptosis is a common mechanism that maintains the homeostatic environment. 
There are two pathways of apoptosis; intrinsic and extrinsic. Two of the most studied 
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genes of the intrinsic pathway of apoptosis are previously mentioned Tp53 gene and the 
B-cell lymphoma 2 (BCL-2) family [49].  
 The p53 protein is a key component in the regulation of apoptosis in cells. To re-
view from the previous section, p53 is normally bound to Mdm2. Ubiquitination of p53 
results in its transport to the proteasome for degradation. Cells typically have low levels 
of p53 expression until there is cellular or genetic stress. When the cell experiences stress 
Mdm2 is phosphorylated and unbound from p53 where it is stabilized to act on down-
stream targets including pro-apoptotic  proteins in the BCL-2 family [49].  
 There are two groups in the BCL-2 family, pro-apoptotic and pro-survival pro-
teins. Both pro-apoptotic and pro-survival proteins are important for the function of the 
mitochondria’s outer membrane by countering each others signaling to regulate the apop-
tosis hallmark of cancer [50].  
 The pro-apoptotic BCL-2 family of proteins includes four main proteins NOXA, 
PUMA, BAX and BAK [51]. When a cell is not undergoing cellular stress the pro-apop-
totic regulators are not activated by p53 and anti-apoptotic BCL-2 blocks apoptotic sig-
naling factors. During times of cellular stress, the pro-apoptotic regulators NOXA and 
PUMA are activated by stabilized p53. NOXA and PUMA then activate two more pro-
apoptotic proteins, BAX and BAK. BAX and BAK are normally inhibited by anti-apop-
totic BCL-2 preventing the cell from undergoing apoptosis. When anti-apoptotic BCL-2 
signaling is repressed by NOXA and PUMA, BAX and BAK are able to initiate apoptosis 
by making the outer membrane of the mitochondria porous in a process called: mito-
chondrial outer membrane permeabilization (MOMP). Once MOMP begins, it is irre-
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versible and the cell is forced to complete apoptosis. Following MOMP, the mitochondria 
releases cytochrome C [51][49]. Cytochrome C is a heme protein that functions within 
the electron transport chain by transporting electrons during energy production in the mi-
tochondria [52] Cytochrome C then binds to APAF-1 and caspase 9 creating an apopto-
some. The apoptosome signals further caspase cascades ending in programmed cell death 
[51][49].  
 Due to the nature of the tumor environment, cancer cells are under constant genet-
ic and cellular stress. In normal physiological conditions this stress would cause the cell 
to upregulate p53 and undergo apoptosis [53]. One of the hallmarks of cancer is to ac-
quire mutations in order to overcome normal homeostatic apoptotic signaling. Two of the 
most commonly mutated genes in cancers are tp53 (p53) and BCL-2. Mutations in tp53 
(p53) account for 50% of all cancer cases [54]. Those who are diagnosed with breast can-
cer commonly have mutations in the tp53 (p53) gene that is correlated with more aggres-
sive forms of breast cancer [55].  
 Increased expression of anti-apoptotic BCL-2 is associated with poor prognosis in 
most cancers. This is because the balance between anti- and pro- apoptotic signaling 
would then be in favor of tumor survival during genetic and cellular stress [55]. Interest-
ingly, increased BCL-2 is associated with a more favorable prognosis in breast cancer. 
Breast cancer patients with elevated BCL-2 expression have slower proliferation, de-
creased tumor size and absence of p53 mutations [56] [57]. However, the mechanisms are 
not well understood but could be related to hormone receptor status as triple negative 
breast cancers do not experience this effect [57]. 
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   MAP Kinase Signaling Pathway  
 One of the most commonly mutated pathways in cancer is the mitogen-activated 
protein (MAP) kinase pathway [58]. The MAP kinase pathway is responsible for cell pro-
liferation and survival. This pathway is initiated by a variety of growth factors that acti-
vate transmembrane receptor tyrosine kinase (RTK). One example of the initiation of an 
RTK, is the heterodimerization of HER2 with HER1/3/4 in response to ligand binding, 
activating the MAP kinase pathway [59]. A main component of the MAP kinase pathway 
is the guanosine triphosphate (GTPase), RAS. Normally RAS is bound to GDP in the 
“off” state. When a phosphate group is bound to RAS, RAS undergoes a conformational 
change activating the protein into the “on” state [59]. RAS is then free to phosphorylate 
other downstream proteins such as RAF. RAF then phosphorylates MEK which activates 
ERK 1/2. ERK is then able to enter the nucleus to act as a transcription factor for genes 
that increase cell growth and survival. One of the functions of the MAP kinase pathway is 
regulating cyclin D, the previously mentioned initiator cyclin in the cell cycle. Increased 
expression of cyclin D allows the cell to pass through cell cycle to divide and surpass cell 
cycle checkpoints even under oncogenic stress. At any point of this pathway a cell may 
acquire a mutation causing the pathway to constitutively stay active, leading to the forma-
tion of cancer cells. The most common of these mutations is found in RAS [59]. 
Activating invasion and metastasis 
 In order for cancer cells to survive, they may acquire the hallmark of invasion and 
metastasis. Once primary tumor cells have mutated to proliferate indefinitely and evade 
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apoptotic mechanisms, cells may gain the ability to enter the vascular system and create a 
secondary tumor [35]. Metastasis of the primary tumor is the most common cause of 
death in women who are diagnosed with breast cancer [60].  
 Breast cancer tumors are a form of carcinoma that arise from mutated epithelial 
cells [61]. As the primary tumor grows, the cells deep in the center become hypoxic due 
to the leaky, poorly constructed vasculature. The poorly constructed vascular environ-
ment is unable to provide the tumor cells with the appropriate nutrients and oxygen 
putting the cancer cells at risk of death. The lack of nutrients forces the cancer cells to 
mutate in order to invade and metastasize to a secondary location with a more viable en-
vironment [60].   
 Before primary cancer cells can metastasize they must undergo epithelial to mes-
enchymal transition (EMT) [61]. EMT causes physical changes in the cancer cells such as 
shape, mobility and adhesiveness to the extracellular matrix (ECM) [61]. In order to in-
travasate the vascular system, breast cancer cells must detach from the extracellular ma-
trix and degrade the basement membrane [62].  
 Once the breast cancer cell undergoes EMT and enters the vascular or lymphatic 
systems in its mesenchymal form, the cell is carried to a secondary site. Breast cancer 
commonly metastasizes to the lung, liver and bone [63]. In order to create a secondary 
tumor in the distal site, mesenchymal cells return to their epithelial morphology in a re-
verse process known as mesenchymal-to-epithelial transition (MET). After colonization 
of the secondary tumor, cancer cells may become hypoxic again forcing the tumors to 
undergo metastasis to a tertiary site [60]. 
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 Each phase of metastasis (EMT/circulation/ MET) possesses biomarkers that dif-
ferentiate between the stages. The biomarkers that discern between each phase of metas-
tasis are E-cadherin, intermediate filament vimentin and N-cadherin.  
 In epithelial cells, the function of E-cadherin is to anchor the cell to the ECM. In 
order to metastasize, cancer cells down-regulate E-cadherin so that the cells separate 
from the extracellular matrix allowing them to become motile. Lowered expression of E-
cadherin is found as cancer cells begin EMT [60]. Vimentin’s normal function is to main-
tain a cell’s shape. Cells typically have low expression of vimentin. When the cell enters 
the vascular system the cell experiences higher levels of vimentin expression in order to 
maintain the fibroblastic cell shape [64]. N-cadherin’s normal function is to increase pro-
tease production. N-cadherin expression in cancer cells is important when the cells enter 
the bloodstream to break down the vascular wall. When the cells intravasate and ex-
travasate the vascular system there is an increase of N-cadherin. Cells that lack N-cad-
herin expression are unable to undergo metastasis [60].  
 Once the breast cancer cell has successfully metastasized to secondary organs or 
tissues they break down the extracellular matrix and bind to transmembrane receptors 
called integrins. Integrins allow the breast cancer cell to adhere to the secondary extracel-
lular matrix. Once bound, breast cancer cells begin proliferating at the new location [65]. 
1.4 Importance of non-coding RNA in Breast Cancer  
 Historically, ribonucleic acid (RNA) were thought to have limited function one of 
which was to work as a messenger between DNA and protein or messenger RNA 
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(mRNA). The development of next generation sequencing has allowed for the identifica-
tion of many other classes of RNA that do not encode proteins, termed non-coding RNA 
(ncRNA). NcRNAs make up 99% of the RNA found in mammalian cells [66]. This class 
of RNA contains many subtypes including small non-coding (e.g., microRNA (miRNA)) 
and long non-coding RNA (lncRNA) as well as ribosomal RNA (rRNA) and tRNA 
(tRNA). 
 MiRNAs are the most studied class of small ncRNA and have a well established 
and documented role in the initiation, progression and metastasis of breast cancer [67]. 
MiRNAs are single stranded RNA molecules that range from 21-25 nucleotides in length 
[68]. One specific miRNA, miR-140-5p, has been shown to specifically regulate pheno-
types in breast cancer cells. Overexpression and inhibition experiments showed that in-
creased amounts of miR-140-5p decreased proliferation and invasion of breast cancer 
cells. Therefore expression of miR-140-5p reduces the ability of breast cancer cells to 
metastasize, meaning miR-140-5p has tumor suppressor characteristics [69].  Many 
miRNAs possess tumor suppressive qualities that allow them to prevent cancer develop-
ment in normal cells and reduce cancer cell populations. Although, some miRNA’s are 
capable of acting as oncogenes by increasing expression and promoting cancer-related 
properties [69]. One example of a miRNA with oncogenic properties is miR-203. Elevat-
ed expression of miR-203 maximizes cancer’s ability to create new surrounding vascular 
[70]. MiR-21 expression has also been associated with more aggressive stages of breast 
cancer and decreased survival [71]. Finally, miR-182 has specifically been identified as 
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an oncogene in breast cancer and associated with more aggressive breast cancer cell lines 
[71] 
1.5 TsRNA 
 One type of non-coding RNA, transfer RNA (tRNA), assists in the creation of 
polypeptide chains by delivering amino acids to the ribosome during translation [72]. 
Following RNA polymerase III transcription within the nucleus, immature tRNA have 
both 5’ and 3’ tails. The 3’ tail is cleaved by RNase Z, resulting in a 16-48 nucleotide long 
strand of RNA ending in a polyuracil tail known as tRNA derived small RNA (tsRNA). 
The 5’ tail of the immature tRNA is cleaved by RNase P [73]. tsRNAs differ other tRNA 
derived fragments (TRFs) because tsRNA are cleaved from the immature tRNA in the 
nucleus while other TRFs are cleaved from mature tRNA in the cytoplasm [67]. tsRNAs 
were previously thought to be a non-functional byproduct of the maturation of tRNA 
[67]. Although recent evidence suggests tsRNA may have a biological purpose [72]. 
 TsRNA share similar physical characteristics to miRNAs, such as their size and 
single stranded RNA structure [67]. In fact, several tsRNAs were mistaken for miRNA 
before they were reclassified as tsRNA. For example miR-3676 and miR-4521 were 
found to be ts-101 and ts-53 through northern blot analysis [73]. Since miRNA share a 
similar structure to tsRNA and were previously mistaken for miRNA there is reason to 
believe that tsRNA may have similar functions as miRNA. 
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 Additionally, previous research of tsRNA found that two tsRNA, ts-101 and ts-53, 
had been down-regulated in chronic lymphocytic leukemia (CLL) and lung cancer show-
ing that tsRNA may have a functional role in cancers [67]. ts-53, ts-47 and ts-46 were 
also found to be down-regulated in two lung cancer cell lines. Following overexpression 
of ts-53, ts-47 and ts-46 in two lung cancer cell lines researchers found that colonies had 
decreased proliferation within the colonies. This finding is further supporting evidence 
that tsRNA may have mechanistic properties in cancer and possibly breast cancer [67]. 
1.6 Background and Supporting Data 
 To investigate a potential role of tsRNA in breast cancer, our group profiled tsR-
NA expression in mammary epithelial and cancer cell lines. The normal-like epithelial 
cell line, MCF10A, are immortalized mammary epithelial cells of a 36 year old female. 
The MCF10A is the benign, parental cell line that was transformed using mutated RAS 
into the pre-malignant MCF10AT cell line and finally into the aggressive metastatic 
MCF10CA1a cell line . RAS, as previously mentioned, is a GTPase that works to convert 
GDP to GTP. RAS functions as an oncogene when mutated because it causes dysfunction 
in the MAP kinase pathway resulting in increased proliferation and decreased cell death 
[58]. MCF7 is representative of estrogen/progesterone receptor positive and HER2 pro-
tein negative breast cancer. MDA-MB-231 is a model for triple negative breast cancer 
[73]. From a custom microchip array of 113 known tsRNA, two were identified as a spe-
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cial interest in breast cancer; ts-2 and ts-112. Both ts-2 and ts-112 are detected at low lev-
els in the MCF10A normal mammary epithelial cell line and have increased expression in 




B) Rt-qPCR Expression Normalized to U6 
and MCF10A
Legend 
MCF10A: normal-like epithelial cells 
MCF10AT1: pre-malignant breast cancer cells 
MCF10CA1a: metastatic breast cancer  
MCF7: Estrogen/Progesterone positive  
MDA-MB-231: triple negative breast cancer  
H9 hES: stem cell 
A) Heat Map of ts-2 and ts-112 Ex-
pression in Breast Cancer Cell Lines
 Further, ts-2 and ts-112 are the tsRNAs with the highest expression in female hu-
man embryonic stem cells (H9 hES) compared to MCF10A cells (Figure 1.3.B). RT-
qPCR validation of the MCF10CA1a aggressive breast cancer cell line resulted in a ten-
fold higher expression of ts-2 and ts-112 than in the normal-like MCF10A mammary ep-
ithelial cell line (Figure 1.3.B). For these reasons we hypothesize that ts-2 and ts-112 
promote breast cancer characteristics. 
To further study the effects of tsRNA in cancer our goal was to characterize the function 
of ts-2 and ts-112 in normal breast epithelial compared to aggresive breast cancer cells. 
The first aim of the project is to determine the function of ts-2 and ts-112 using Dharma-
con miRIDIAN hairpin inhibitors that are transfected into the aggressive MCF10CA1a 
breast cancer cell line in vitro followed by phenotypic assays. Phenotypic assays will ana-
lyze for proliferation, cell survival, cell cycle and wound healing. We hypothesize that 
inhibiting ts-2 and ts-112 in the MCF10CA1a cell line will result in a decrease in cancer 
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Figure 1.3 A.) Heat map showing ts-2 and ts-112 expression in breast cancer cell 
lines. Using a microchip array of 113 different tsRNA variants (a small sample is 
shown) we created a heat map showing gene expression in 5 increasingly aggres-
sive breast cancer cell lines. The MCF10a cell line represents normal like breast 
cells and MCF01CA1a is a model for aggressive breast cancer. Blue represents 
lower expression and red shows higher expression of the particular tsRNA. From 
this heat map ts-2 and ts-112 appear to have high expression in aggressive breast 
cell lines. Modified image from Ballatti et al., 2017. B.) RT-qPCR expression 
normalized to U6 and MCF10A. Comparing increasingly aggressive breast can-
cer cells to the H9 hES embryonic stem cell line using qPCR to look for gene 
expression we see that ts-2 and ts-112 are both expressed at higher rates with 
more aggressive cell lines and embryonic stem cell lines. Analyzed using delta 
delta CT method. U6 was used as housekeeping gene. N=1. 
related phenotypes. The second aim to further investigate the function of ts-2 and ts-112 
is to overexpress both tsRNAs in the normal-like MCF10A breast cancer cell line using 
plasmids that are driven by polymerase III. To assess ts-2 and ts-112 overexpression phe-
notypes the previously mentioned phenotypic assays will be conducted. We hypothesize 
that overexpression of ts-2 and ts-112 in the normal-like breast epithelial MCF10A cell 
line will increase cancer related phenotype. 
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Chapter 2: Inhibition and overexpression of tsRNA  
 To date, there is little known about the expression of tsRNA and their mechanistic 
role in cancer. For this reason there are only a few studies supporting tsRNA characteris-
tics in cancer. Two other identified tsRNA, ts-46 and ts-47, both had decreased expres-
sion in chronic lymphocytic leukemia (CLL) and lung cancer. In one experiment analyz-
ing population growth following the overexpression of both ts-46 and ts-47 in lung can-
cer cell lines suppressed lung cancer cell growth. The decreased expression of the two 
tsRNAs, ts-46 and ts-47, in more aggressive CLL and lung cancer cell lines may mean 
both tsRNAs have a tumor suppressive role in cancers [73]. These data give evidence that 
tsRNAs may have a functional role not only in a variety of cancer but possibly breast 
cancer.   
 Findings from previous tsRNA research can be related to the study of ts-2 and 
ts-112. As stated in chapter one, ts-2 and ts-112 are significant because they have more 
expression with increasingly aggressive breast cancer cell lines (Figure 1.3.A) and em-
bryonic stem cell line H9 hES (Figure 1.3.B). Both ts-46 and ts-47 have opposite effects 
on cancer populations as possible tumor suppressors by reducing the size of colonies. 
Since ts-2 and ts-112 are expressed higher in more aggressive cell lines they may possess 
the reciprocal effect as tumor promotors. [67]. We hypothesize that inhibiting ts-2 and ts-
112 in the aggressive breast cancer cell line, MCF10CA1a, will show a decrease in breast 
cancer characteristics and overexpression of ts-2 and ts-112 in the normal-like mammary 
epithelial MCF10A cell line will result in an increase in breast cancer.  
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 The first aim of the project is to inhibit ts-2 and ts-112 using a custom Dharmacon 
miRIDIAN hairpin inhibitor transfected into aggressive breast cancer cell line, MCF10-
CA1a. Following inhibition of ts-2 and ts-112, phenotypic assays will be conducted to 
analyze their role of ts-2 and ts-112 in proliferation, wound healing and cell cycle. We 
anticipate that inhibiting ts-2 and ts-112 will result in a reduction of cancer characteris-
tics.  
 Aim two is to overexpress ts-2 and ts-112 in the normal-like mammary epithelial 
cell line, MCF10A using a custom plasmid, pSuper.gfp/neo that utilizes the backbone 
supplied by OligoEngine. Plasmid expression will be driven by polymerase III and plas-
mids that have been tagged with GFP to assure for proper transfection. There is no cur-
rent literature on the effects of overexpression of tsRNAs on cancer let alone ts-2 and 
ts-112. We hypothesize that the overexpression of ts-2 and ts-112 in the normal-like 
mammary epithelial MCF10A cell line will have the opposite result as the inhibition as-
says by having an increase in breast cancer characteristics.  
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Part A) Inhibition of ts-2 and ts-112  
Growth of Viable Cells Following tsRNA Inhibition 
 To determine the function of ts-2 and ts-112 in metastatic breast cancer and ana-
lyze their participation in cell growth the MCF10CA1a aggressive breast cancer cell line 
was transfected with custom Dharmacon miRIDIAN hairpin inhibitors. Custom inhibitors 
were designed to bind and sequester targeted small RNA molecules in a sequence-specif-
ic manner. The custom negative control inhibitor was designed against cel-miR-39-3p, a 
C. elegans miRNA not expressed by mammalian cells. The negative control was tagged 
with fluorescent dye, Dy546, that allows for confirming transfection and the efficiency of 
the the miRIDIAN hairpin inhibitors. 
 MCF10CA1a cells were then transfected with either custom negative control in-
hibitors with Dy546, ts-2 or ts-112 inhibitor. The mock sample did not contain any in-
hibitor. Each sample was plated at a density of 1,000,000 cells per 10mL tissue culture 
treated plate for each sample (negative control/ts-2 inhibition/ ts-112 inhibition/mock). 
Twelve hours following transfection 100,000 cells from each sample were plated as trip-
licates in 2mL six-well tissue culture treated plates. Following plating, samples were as-
sessed for cell viability in 24-hour intervals for 48 hours using a Trypan-blue exclusion 
assay. Inhibition of ts-2 resulted in cell growth similar to that of mock and negative con-
trols  
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 Inhibited ts-112 resulted in decreased cell growth at the 24 hour time point com-
pared to mock and negative controls with an initial decrease in cell growth of 26%. A t-
test was done to assess the statistical similarities between the negative control and inhib-
ited tsRNAs. Inhibited ts-2 statistically compared to negative control resulted in a non-
significant p-value of 0.61. Inhibited ts-112 resulted in a non-significant p-value of 0.425. 
Following inhibition of ts-2 cell growth did not change compared to negative and mock 
controls. Using a t-test to compare inhibited ts-2 to the negative control revealed a non-
significant P-value at both 0-24 and 24-48 hour time points (Figure 2.1). 
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Figure 2.1: Growth of viable cells following ts-2 and ts-112 inhibition.Viable cell 
growth curve of ts-2 and ts-112 following inhibition revealed that ts-112 had an initial 
decrease in growth, from the 0hr to 24hr cell counts. The slope of ts-112 inhibition 
returns to similar amounts as mock and negative controls during the 24hr and 48hr 
time frame. ts-2 inhibition showed similar growth to mock and negative controls. N=3 
and the error bars represent standard error of the mean. 
Growth Curve of Viable Cells Following ts-2 and ts-112 Inhibition 
 This results indicate that inhibiting ts-112 results in an initial decrease in cell 
growth followed by cell growth similar to other controls. Cell growth following ts-2 inhi-
bition is similar to negative and mock controls through all time points. This finding leads 
us to question whether inhibition of ts-2 and ts-112 result in a decrease in doubling time 
in the aggressive MCF10CA1a breast cancer cell line. 
Doubling Time Following tsRNA Inhibition  
 To further investigate the function of ts-2 and ts-112 in the aggressive MCF10-
CA1a breast cancer cell line, population doubling time was calculated from the previous-
ly created growth curve (Figure 2.1) following inhibition. The doubling time for the cel-
miR-39-3p negative control was calculated and compared to either inhibited ts-2 or 
ts-112 doubling times.  
 ts-2 inhibition showed a 7% increase in doubling time at 14 hours compared to the 
negative control that doubled at 12.5 hours (Figure 2.2). ts-112 inhibition did not show as 
robust doubling time results and had a doubling rate of 12.5 hours as did the negative 
control (Figure 2.2). The data suggest that ts-2 plays a role in decreasing aggressive 






 The inhibition of ts-112 did not show as great of a difference in doubling time as 
the inhibition of ts-2. Analyzing the doubling time of ts-112 did not answer the question 
as to why the cells were initially growing slower 24 hours following inhibition. This data 
showed that ts-2 inhibition increased doubling time although, our previous assay looking 
at cell growth showed that there was no change in cell growth compared to negative con-
trols.  ts-112 inhibition showed no sign of increase in doubling time but in the previous 
assay showed an initial decrease in cell growth which lead us to believe that ts-2 and 
ts-112 may have an effect on apoptotic or cell death mechanisms. This is because there 
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Doubling Time Following Inhibition of ts-2 and ts-112 in MCF10CA1a 
Figure 2.2: Doubling time of aggressive MCF10CA1a cells following ts-2 and 
ts-112 inhibition. To analyze cell growth following inhibition of ts-2 and ts-112 in 
the aggressive MCF10CA1a breast cancer cell line, cells were counted using an au-
tomated counter following a trypan blue exclusion assay. Ts-2 inhibition showed a 
7% increase in doubling time from 12.5 hours to 14 hours (Fig. A), while ts-112  
displayed a minimal increase compared to negative controls (Fig. B).
A) B)
appears to be unexplained mechanistic correlation between the inhibition of ts-2 and 
ts-112 and cell growth and doubling time. 
Trypan Blue Exclusion Following Inhibition of ts-2 and ts-112  
 Following analysis of cell growth and doubling time of aggressive MCF10CA1a 
breast cancer cells, ts-2 and ts-112 were analyzed for their function in cell death. 
MCF10CA1a breast cancer cells (500,000) were plated in  
non-coated tissue culture treated 6-well plates. MCF10CA1a cells were then transfected 
with the same previously mentioned custom miRIDIAN hairpin inhibitors of ts-2 or 
ts-112 that bind-to and sequester targeted small RNA molecules. The previously men-
tioned negative control that was labeled with dye, Dy546, was  used again in this experi-
ment. Plates were analyzed for cell death 36 and 60 hours following transfection by try-
pan blue exclusion on an automated counter.  
 Analyses of cell death at 36 hours following inhibition of ts-2 resulted in 4% of  
aggressive breast cancer cell death compared to 3.0% in negative controls. At 60 hours 
post-transfection, ts-2 inhibition resulted in cell death of 3.2% while the negative control 
experienced 1.7% cell death. Following inhibition of ts-112 trypan blue exclusion analyz-
ing cell death in the aggressive breast cancer cell line at 36 hours resulted in a 6% cell 
death and the negative control experienced a 3.0% cell death. At 60 hours post-transfec-






 This data suggests that both ts-2 and ts-112 may have involvement in apoptotic 
mechanisms in aggressive breast cancer due to their increased cell death compared to 
negative controls. Although, inhibition of either tsRNA does not result in a statistically 
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Cell Death Following ts-2 and ts-112 Inhibition in MCF10CA1a
Figure 2.3: Cell death analysis following ts-2 and ts-112 inhibition. 
Cell death was analyzed by Trypan blue exclusion assay on an auto-
mated cell counter. Inhibition of ts-2 revealed cell death of 4% at 36 
hours and 3% cell death at 60 hours post-transfection (Fig. A). Inhibi-
tion of ts-112 resulted in 6% cell death at 36 hours post-transfection  
and 2.8% cell death 60 hours post transfection compared to negative 
controls (Fig. B). Neither outcome was statistically significant. N=3 
and error bars are standard error of the mean.
A) B)
significantly outcome thus further exploration into ts-2 and ts-112’s role in apoptosis is 
necessary.  
 The initial decrease in MCF10CA1a cells following ts-112 inhibition seen in the 
viable cell growth curve could be explained by the decrease in cell growth 24 hours fol-
lowing transfection. Inhibited MCF10CA1a cells may be dying faster as a population 
therefore there are less living cells to count leading to a decreased initial population 
growth curve. After analyzing for cell growth, doubling time and death we then ques-
tioned the effects of tsRNAs on metastatic breast cancer cells ability to migrate.  
 At the 36hr time point MCF10CA1a cells following ts-112 inhibition resulted in 
6% cell death (Figure 2.3.B). The increase of cell death following trypan blue exclusion 
could explain why there was a decrease in population cell growth (Figure 2.1). Our hy-
pothesis is that the initial increase in population cell death explains why there is an initial 
decrease in population cell growth. We reasoned this because if the population of cells is 
dying they can not be dividing.  
Scratch Assay Analyzing Cell Motility Following ts-2 and ts-112 inhibition 
 To analyze cell motility and migration in the aggressive MCF10CA1a breast can-
cer cell line, ts-2 and ts-112 were inhibited by transfecting cells with previously men-
tioned custom Dharmacon miRIDIAN hairpin inhibitors followed by a scratch assay. 
 Scratch assays were conducted by initially plating the aggressive MCF10CA1a 
breast cancer cell line at 1.50x106 cells per well in a tissue culture treated six well plate. 
MCF10CA1a cells were transfected with the previously mentioned negative control la-
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beled with fluorescent dye, Dy546 or hairpin inhibitors for either ts-2 or ts-112. Follow-
ing transfection, cells were kept in reduced serum media. Twelve hours post-transfection 
cells were scratched with a 200uL pipette tip in a cross hatch pattern. Images were taken 
at 4x and 10x at the zero hour time point and every four hours for 16 hours following the 
initial scratch (Figure 2.4.A). Images were taken in the same location. Raw scratches 
were then turned into a numerical value through the MiToBo plugin on ImageJ (Figure 
2.4.B). 
 The inhibition of ts-2 and ts-112 did not show a difference in wound healing time 
compared to negative controls. ts-112 revealed a very slight decrease compared to other 
controls but it was not significant (Figure 2.4.C). 
 From our previous data we can conclude that both ts-2 and ts-112 have a limited 
mechanistic effect in aggressive breast cancer cell growth, doubling time and cell death 
as proven by past analyses. Additionally, inhibition of ts-2 and ts-112 has minimal to no 













Figure A) Raw Images of Wound Healing at 4x 




























Cell Cycle Analysis using Flow Cytometry  
 To investigate the function of ts-2 and ts-112 during the cell cycle, tsRNAs were 
inhibited using previously stated custom Dharmacon miRIDIAN hairpin inhibitors that 
were transfected into the MCF10CA1a aggressive breast cancer cell line. Following 
transfection, cells were then fixed with ethanol and stained with propidium iodide RNase 
staining buffer and were analyzed using flow cytometry to assess cell cycle distribution. 
Flow cytometry results showed the quantity of cells in each phase of the cell cycle repre-
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Figure C) Percent Wound Open
Figure 2.4: Wound healing time following ts-2 and ts-112 inhibition. To analyze 
wound healing time after ts-2 and ts-112 have been inhibited in the MCF10CA1a 
using a scratch assay, we took images of the cells for 16 hours every 4 hours at 4x 
and 10x. Represented images are in 4x (Fig. A). We then took the raw images and 
made them binary using the MiToBo plugin on ImageJ (Fig. B). Between 4-16 
hours inhibited ts-112 samples had increase in cell motility (Fig. C). The sample 







sented by the area of the peaks (Figure 2.5.A). The first peak represents the number of 
cells in G1 and the second peak represents the number of cells in G2/M. Cell counts be-
tween the G1 and G2/M peaks represent the amount of cells in S phase (Figure 2.5.A). 
The raw data was analyzed with Modfit software to model cell cycle phases and convert-
ed into a bar graph.  
 Inhibition of ts-2 had 90.2% of cells in G1 and 6.5% of S phase (green) and 3.3% 
of cells in G2/M phase (Figure 2.5.E). Inhibition of ts-112 resulted in 86.2% of cells in 
G1, 9.0% in S phase (green) and 4.81% of cells in G2/M phase (Figure 2.5.E). For com-
parison, negative controls had 88.2% of cells in G1 phase, 8.0% in S phase (green) and 
3.8% of cells in G2/S phase (Figure 2.5.E). Cell cycle analysis following ts-2 inhibition 
did not result in a significant difference between cells in either phase of the cell cycle. 
Error bars are representative of the standard error of the mean. Compared to negative 
controls inhibition of ts-112 resulted in a statistically significant increase of cells in S 
phase and decrease of cells in G1 phase with a P-value less than 0.05 compared to nega-
tive controls. 
 The major finding of this assay was that the inhibition of ts-112 resulted in a sta-
tistically significant increase of cells in S phase and decrease in G1 phase indicating that 
ts-112 may be involved in cell cycle regulation. Although, it is not clear from analyses of 







Raw Peaks from Cell Cycle Analysis using Flow Cytometry  























Figure E) Cell Cycle Analysis using Flow Cytometry 
Following ts-2 and ts-112 inhibition
Figure 2.5 Cell cycle analysis following ts-2 and ts-112 inhibition. Following 
inhibition of ts-2 and ts-112 in the aggressive MCF10CA1a breast cancer cell 
line, we observed cell cycle using flow cytometry. Flow cytometry resulted in  
raw peaks where the first peak is representative of the amount of cells in 
G1phase and the second peak the G2/M phase. In between the two peaks is 
representative of the amount of cells in S phase (Figure A-D). The peaks re-
veal an increase of cells in S phase and decrease of cells in G1 phase follow-
ing ts-112 inhibition. This data was then turned into a bar graph to better vi-
sually assess the differences in cell cycle following inhibition of ts-2 and 
ts-112 (Figure E). Inhibition of ts-112 revealed a statistically significant (P <.
05) increase of cells in S phase and decrease in G1 phase (Figure E).  N=3. 














RT-qPCR to Analyze Candidate Check Point Genes  
 Following the statically significant increase of MCF10CA1a cells in S phase and 
decrease in G1 phase after ts-112 inhibition we conducted RT-qPCR analysis of candidate 
checkpoint genes to further analyze the effects of tsRNA on cell cycle.  
 The following nine genes associated with checkpoint or mechanisms of cellular 
replication were selectively chosen: CDKN1 (p21), ATR, ATM, CCNA2, CCNE1, 
CHEK1, CHEK2, SRSF3, BCL-2 and tp-53. To review from chapter one, CDKN1 (p21) 
functions by regulating the cells ability to pass through the G1/S phase and G2/M phase 
checkpoints. ATR and ATM function by phosphorylating the p53 protein which regulates 
the G1/S and G2/M phase checkpoints. CCNA2 and CCNE1 are both genes that encode 
cyclin regulators of the cell cycle. CHEK1 and CHEK 2 both regulate the initiation of 
DNA damage checkpoints at both G1/S and G2/M phase checkpoints. The presence of 
SRSF3 is needed in order for the cell to pass through the G1/S phase checkpoint. BCL-2 
is a regulator of the intrinsic pathway of cell death.  
 All RT-qPCR’s used 60S RPL13a ribosomal protein RNA as the housekeeping 
gene. The result of these assays showed that inhibition of ts-2 or ts-112 did not result in 
changes of these candidate cell cycle genes. Data were analyzed using the delta delta CT 




Table A) RT-qPCR inhibition of ts-2 and ts-112 Compared to Candi-









RPL13a 1.000 1.000 1.000 1.000
CDKN1A 
(p21)
1.006 0.898 0.971 0.970
ATR 1.002 0.997 0.999 1.000
CCNA2 1.002 0.994 0.990 0.998
CCNE1 1.000 0.996 0.999 0.999
CHECK1 1.001 0.999 0.997 0.998
CHECK2 1.000 0.999 1.001 0.999
SRSF3 0.991 0.959 0.973 0.989
BCL2 1.000 1.000 0.999 0.999









RPL13a 1.000 1.000 1.000 1.000
CDKN1A 
(p21)
1.006 0.898 0.971 0.970
ATR 1.002 0.997 0.999 1.000
CCNA2 1.002 0.994 0.990 0.998
CCNE1 1.000 0.996 0.999 0.999
CHECK1 1.001 0.999 0.997 0.998
CHECK2 1.000 0.999 1.001 0.999
SRSF3 0.991 0.959 0.973 0.989
BCL2 1.000 1.000 0.999 0.999
Tp53 (p53) 0.995 0.995 0.962 0.974
Table B) RT-qPCR inhibition of ts-2 and ts-112 Compared to Candidate 
Genes in Negative  Controls
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Table 2.1 Analysis of Candidate Cell Cycle Genes following ts-2 and ts-112 inhibi-
tion. We compared ts-2 and ts-112 to candidate checkpoint genes in the MCF10-
CA1a aggressive breast cancer line at 24 and 48 hour time points using RT-qPCR. 
RPL13a was used as the housekeeping gene. Compared to the control there was no 
change when using the delta delta CT method for either inhibited ts-2 or ts-112 
compared to mock (Table A) or negative controls (Table B). Both mock and nega-
tive control were biological triplicates in one qPCR plate.
Inhibition Discussion 
 To characterize the function of ts-2 and ts-112 in the aggressive MCF10CA1a 
breast cancer cell line, we inhibited ts-2 and ts-112, which are both expressed at elevated 
levels in increasingly more aggressive breast cancer cell lines. The MCF10CA1a cell line 
is representative of stage IV or distal metastatic breast cancer. In order to characterize the 
function of tsRNAs in aggressive or metastatic breast cancer we utilized phenotypic as-
says to investigate ts-2 and ts-112’s role in the hallmarks of cancer. The hallmarks of can-
cer that were studied were: replicative immortality, evasion of cell death and activating 
metastasis [35]. The phenotypic assays that were conducted following inhibition of ts-2 
and ts-112 were: growth curve of viable cells, doubling time, trypan blue exclusion, 
scratch assay to assess motility, flow cytometry to assess cell cycle and RT-qPCR to ana-
lyze candidate checkpoint genes. We hypothesized that following ts-2 and ts-112 inhibi-
tion in the aggressive MCF10CA1a breast cancer cell line there would be a decrease in 
cancer characteristics.  
 The major finding of the growth curve analysis counting viable cells in the ag-
gressive breast cancer cell line MCF01CA1a following inhibition of tsRNAs showed that 
knocking down ts-112 resulted in a decrease in population cell growth. Between 0-24 
hours ts-112 inhibited cells experienced a decrease in population cell growth. In the 
24-48 hour time point, ts-112 transfected cells allowed growth rates similar to those of ts-
2, mock and negative controls although the population as a whole remained lower than 
the negative control. The inhibition of ts-2 did not result in a significant difference rela-
tive to negative and mock controls (Figure 2.1). 
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 Using the graph we generated using Graphpad Prism (Figure 2.1) to analyze the 
growth curve of viable cells it is clear that ts-112 has an effect on cell proliferation. When 
ts-112 is knocked down there is a decrease in viable population cell growth meaning that 
ts-112 appears to have a mechanistic significance in the continuation of aggressive or 
metastatic breast cancer divisions. This thought can be proven by analyzing the other 
three controls of the study- mock, negative control and inhibited ts-2. In these three con-
trols cells were all dividing at the same rate and contained ts-112. Since ts-2 inhibition 
did not result in a decrease in cell growth this tsRNA may not have a functional role in 
cell death and proliferation in aggressive breast cancer cell lines. Further validation is 
necessary to prove that ts-112 plays a mechanistic role in aggressive breast cancer sur-
vival.  
 Our hypothesis was that the inhibition of ts-2 and ts-112 would result in a de-
crease in cancer characteristics including cell growth. Since the knock down of ts-112 
resulted in a decrease in cell divisions and cause of cell death during the beginning of the 
cell death experiment this result is in agreement of our hypothesis. This means that ts-112 
may play a mechanistic role in the following hallmarks of cancer: evading apoptosis, un-
limited proliferation and enabling replicative immortality. Evading apoptosis is important 
to note because we assessed for living cells and not dead cells. The inhibition of ts-2 re-
sulted in a growth curve similar to the mock and negative controls. Therefore, the knock-
down of ts-2 in a growth curve assay is in disagreement with our hypothesis. ts-2 when 
present may function by preventing the aggressive MCF10CA1a from dividing but fur-
ther validation using overexpression assays is needed. 
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 Because the growth curve revealed that ts-112 may have a mechanistic role in the 
hallmarks of cancer (enabling replicative immortality and sustaining proliferative signal-
ing), the growth curve assay was followed with a doubling time analysis.  
 In order to further investigate the function of ts-2 and ts-112 in the hallmark of 
cancer, replicative immortality and sustaining proliferative signaling, we looked at the 
doubling time of MCF10CA1a cells following ts-2 and ts-112 inhibition. Analyzing the 
doubling time of aggressive breast cancer cell line MCF10CA1a, we found that inhibited 
ts-2 had an increased ability to divide by 7% compared to negative controls (Figure 2.2). 
Inhibition of ts-112 did not show as robust results as the inhibition of ts-2 because the 
resulting doubling time was similar to those of the negative controls.   
 Our hypothesis was that inhibiting ts-2 and ts-112 would result in a decrease in 
cancer characteristics. The lack of ts-2 prevents the MCF10CA1a cells from successfully 
gaining unlimited replicative immortality and sustained proliferation thus decreasing can-
cer characteristics. Inhibition of ts-112 does not appear to have an effect on doubling time 
which does not necessarily oppose the hypothesis but does not agree with it. This assay 
does support that ts-2 and ts-112 have a mechanistic role in aggressive breast cancer. In 
order for cells to replicate indefinitely they must be able to evade apoptosis.  
 The next assay, trypan blue exclusion, was to assess the effects of inhibition of ts-
2 and ts-112 in the hallmark of cancer, evasion of apoptosis, in the aggressive MCF10-
CA1a cell line. This assay showed that both ts-2 and ts-112 play a regulatory role in ag-
gressive breast cancers ability to overcome apoptosis. Both tsRNAs following inhibition 
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showed an increase in cell death at the 36hr and 60hr time points compared to the nega-
tive control (Figure 2.3).  
 Since there was an increase in cell death following ts-2 inhibition this may ex-
plain the results of the growth curve and doubling time. To reiterate, the viable growth 
curve of ts-2 following inhibition shows a subtle decrease in cell growth, an increase in 
doubling time and a constant increase in cell death compared to negative controls. The 
increase in cell death following ts-2 inhibition may explain why the cells are taking 
longer to double because there are less cells doubling. Although, this does not explain 
why the inhibited ts-2 viable growth curve was similar to the negative control. 
 The inhibition of ts-112 resulted in an overall increase in cell death at the 36 and 
60 hour time points with a much larger initial increase in cell death at the 36 hour time 
point (Figure 2.3.B). This data explains why inhibition of ts-112 in the growth curve had 
an initial decrease in cell growth but did not have an effect on doubling time. The aggres-
sive MCF10CA1a cells with ts-112 inhibition were dying between the first 0-36 hours 
and therefore decreasing the total quantity of viable cells measured. There was no effect 
on doubling time because this data was made from the viable cell growth curve and cell 
death was not taken into account in this analysis. Our hypothesis was that the inhibition 
of ts-2 and ts-112 would result in a decease in cancer characteristics that are associated 
with the hallmarks of cancer. ts-2 inhibition followed by a trypan blue exclusion assay 
was used to assess the cell’s ability to evade apoptosis. The results of this assay is evi-
dence that ts-2 plays a regulatory role in aggressive breast cancer’s ability to evade apop-
tosis because ts-2 is able to increase doubling time.  
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 To further investigate the molecular function of ts-2 and ts-112 in aggressive 
breast cancer we assessed cell motility, a hallmark of cancer that allows a cancer cell to 
metastasize. To analyze motility, a scratch assay was done following inhibition of ts-2 
and ts-112 in the aggressive MCF10CA1a breast cancer cell line. 
This assay did not take proliferation into account because cells were kept in reduced 
serum media. Images were taken of wound/scratch closure at 4x and 10x every four hours 
for sixteen hours. The result of this assay showed that neither ts-2 or ts-112 had a signifi-
cant effect on cell motility (Figure 2.4).  
 During analysis some images appeared to show that the inhibition of ts-112 re-
vealed a robust increase in cell motility. The reason for these discrepancies between sam-
ples may be because the rate of transfection may not have been the same across each of 
the cell culture dishes. Different wounds/scratches may have had more or less ts-2 or 
ts-112 inhibited affecting the results. Further studies could utilize a more consistent way 
of transfection so that all cells received the same amount of inhibitor. Our hypothesis was 
that inhibiting ts-2 and ts-112 would result in a decrease in cancer characteristics. Neither 
of the tsRNAs following inhibition decreased cancer characteristics because they had no 
affect on the wound/scratch healing time; therefore this assay opposes the hypothesis.  
 Following previous assays that showed that ts-2 and ts-112 may play a regulatory 
role in replicative immortality, unlimited proliferation and evasion of cell death, we in-
hibited ts-2 and ts-112 and then analyzed their effect on the cell cycle using flow cytome-
try. The inhibition of ts-2 did not result in a difference between mock and negative con-
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trols although inhibition of ts-112 resulted in a statistically significant (P <0.05) increase 
of cells in S phase and decrease in G1 phase (Figure 2.3.E).  
 This assay concluded that the function of ts-112 has an effect on cell cycle regula-
tion at the G1/S and G2/M phase check points. In order to further investigate the signifi-
cant decrease of cells in G1 phase and increase of cells in S phase following ts-112 inhi-
bition, we analyzed nine candidate checkpoint genes (CDKN1A (p21), ATR, ATM, CC-
NA2, CCNE1, CHEK1, CHEK2, SRSF3, BCL-2 and tp-53) that are associated with the 
normal function of the G1/S and G2/M phase checkpoints. The result of these RT-qPCRs 
showed no change when compared to ts-2 and ts-112 interaction (Table 2.1.A/B). Inhibit-
ed ts-112 and p21 did show a possible interaction at the 24 hour mark (.898) in both 
mock and negative control although the interaction is no longer present at the 48 hour 
mark. Inhibition of ts-112 opposes our hypothesis that there will be a decrease in cancer 
characteristics because the cells are able to pass out of G1 phase and into the S phase 
faster.  
 To further examine specific genes that are associated with ts-2 and ts-112, more 
candidate genes can be analyzed using RT-qPCR techniques. Another analysis that could 
be performed is western blot analysis of candidate proteins or RNA-seq profiling. It is 
unknown how tsRNA function in the cell. MiRNA are able to bind to control post-tran-
scriptional gene expression, to mRNA thus repressing the downstream creation of pro-
teins [74].  Since tsRNA have similar shape and were previously mistaken as miRNA 
they may be able to function in this way. To test our selected candidate genes against ts-2 
and ts-112 could be a future experiment to assess their function on the protein level since 
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there was no correlation on the mRNA level. Another assay to analyze cell cycle in un-
limited proliferation could be to measure the length of time that aggressive breast cancer 
MCF10CA1a cells stay in each phase of the cell cycle. 
 One limiting factor of all of the above experiments is that ts-2 may not respond as 
well to transfection inhibition because it is found at multiple places on the genome  and is 
smaller in length, while ts-112 is found only on one site and longer in size. These factors 
are significant because ts-112 may respond better to transfection than ts-2. ts-2’s custom 
inhibitors may not inhibit as many sequences in the RNA or they may not be able to tar-
get as many sites since they are found on multiple sites. Previous data showed that ts-2, 
when inhibited, had a tsRNA expression rate of 0.8 compared to the negative control of 
1.0. Since ts-2’s transfection quality was not measured, it is unknown how many cells 
actually had ts-2 knocked down. This could also explain why in some of the previous ex-
periments ts-112 had a more robust response compared to ts-2. Future experiments should 
focus on identifying better transfection approaches or finding better inhibitors. In this 
study, we used Lipofectamine 2000, in future experiments Lipofectamine 3000 could be 
used to deliver more tsRNA into the cell line for more robust and accurate results because 
Lipofectamine 3000 is an improved formula of Lipofectamine 2000.  
 The results of the inhibition section suggest that ts-2 and ts-112 both play a role in 
the mechanistic function of metastatic breast cancer because there is a phenotypic re-
sponse to their knock down in the aggressive MCF10CA1a cell line. The overall result of 
ts-2  and ts-112 inhibition shows that both tsRNAs play a regulatory role in the hallmarks 
of replicative immortality, unlimited proliferation and evasion of cell death. Inhibition of 
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ts-2 showed no change in the growth curve, cell motility or cell cycle analysis opposing 
our hypothesis. Inhibition of ts-112 did not have an effect on doubling time or cell motili-
ty also opposing our hypothesis. In order to assure that either tsRNA does not have a reg-
ulatory role in the previous assays, overexpression of ts-2 or ts-112 will validate our find-
ings by either having no effect or the opposite effect. 
 Because the inhibition of ts-2 resulted in an increased doubling time and a small 
increase in cell death, it appears that ts-2 may be necessary for aggressive breast cancer 
survival. From our results we hypothesize that ts-2 has a protective effect on aggressive 
breast cancer cells because in the absence of ts-2 aggressive MCF10CA1a cells are not 
able evade apoptosis and or divide as quickly. The inhibition of ts-112 results suggest that 
ts-112 plays a role in cell growth, cell death and cell cycle regulation meaning that ts-112 
may have mechanistic function in the following hallmarks of cancer: evasion of apopto-
sis, unlimited proliferation and replicative immortality. From the ts-112 inhibition results, 
ts-112 may play a regulatory role in cell cycle, proliferation and replicative immortality, 
therefore supporting the continuation of aggressive or metastatic breast cancer. 
 Future experiments to continue researching tsRNAs function utilizing inhibition 
methods could include performing a microchip of hundreds of genes or RNA expression 
profiling rather then the previously selected candidate genes which showed no effect. Al-
though there was no association of tsRNA with our selected candidate genes there is solid 
evidence that they do have mechanistic value in aggressive breast cancers in their ability 
to evade apoptosis and proliferate indefinitely. Targeting hundreds of genes could give 
better insight into molecular pathways that interact with tsRNAs. To further explore tsR-
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NAs function in the hallmark of unlimited proliferation in aggressive/metastatic breast 
cancer, multiple single cancer cells could be analyzed for their independent growth curve 
and doubling time. This assay would help to validate the population analysis of  the 
growth curve and doubling time to see if a single cancer cell shares the same results. 
  To further analyze how ts-2 and ts-112 function in the evasion of apoptosis fur-
ther apoptosis assays could be done including a TUNEL assay to analyze cell death in a 
single cell. Other apoptotic assays could include analyzing caspase activity in the cells 
following inhibition. As previously stated caspases are a part of the apoptotic pathway. In 
our experiments looking at metastasis we did not explore invasion. Invasion properties 
could be assessed using transwell assays. These assays could give us a better understand-
ing of the function of ts-2 and ts-112 since their function continues to be unknown. 
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Part B.) Overexpression of ts-2 and ts-112 
Results 
Overexpression using Plasmid  
 In order to validate the inhibition experiments, ts-2 and ts-112 were overexpressed 
in normal-like epithelial breast MCF10A cell line using three custom plasmids. Plasmids 
utilized a pSuper.GFP+neo backbone supplied from OligoEngine. The three plasmids 
were: pSUPER.GFP+neo.neg, pSUPER.GFP+neo.ts2 or pSUPER.GFP.ts112. Plasmids 
were encoded to express green fluorescent protein (GFP) to assure that the cells were 
transfected. Plasmids utilized an H1 promotor site for polymerase III which will drive 
expression of the negative control, ts-2 or ts-112. Normal-like mammary epithelial 
MCF10A cells were transfected with custom plasmids using lipofectamine 2000 and 
Opti-Mem in a 1:5 ratio.  
 Multiple transfections of the OligoEngine plasmids resulted in absence of  GFP 
fluorescence in the MCF10A cells. We then performed a RT-qPCR, which resulted that 
there was no detectable GFP mRNA in the transfected cells. In order to assure that trans-
fection methods for overexpression were not the reason for lack of fluorescence, we set 
up a follow-up experiment to test the OligoEngine negative control plasmid (pSU-
PER.GFP+neo.neg) against a known plasmid containing GFP, pmaxGFP. MCF10A cells 
were transfected utilizing the same methods as used in earlier experiments. The only dif-
ference was that we took the negative control plasmid directly from the stock sample 
supplied by OligoEngine rather than growing them in the STBL3 E.coli. cell-line. Fol-
lowing transfection of the known pmaxGFP and stock sample of the OligoEngine nega-
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tive control, cells were observed for fluorescence for twelve hours. The known negative 
control (pmaxGFP) displayed fluorescence while the OligoEngine plasmid did not. 
Bright-field and fluorescent images were taken at 4x twenty four hours following trans-
fection (Figure 2.6).  
 
 The result of this assay concluded that the pSuper.gfp+neo.neg OligoEngine 
plasmid was not properly constructed or that there was a problem with transfection into 
the normal-like epithelial MCF01A cell line. We followed up with the OligoEngine com-
pany with no response and have filed a complaint with the Better Business bureau. Future 
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Analyses of OligoEngine Plasmid Expression
Figure 2.6: Analyses of OligoEngine Plasmid Expression. To analyze 
whether the pSuper plasmids were transfecting into the normal-like 
MCF10a cell line, we transfected this plasmid as well as a known function-
ing GFP plasmid, pmaxGFP  as a positive control, into a 10mL petri dish. 
Images were taken 24 hours following transfection at 4x. The pmaxGFP 
showed fluorescence while the pSuper OligoEngine plasmid did not, thus 
showing that the OligoEngine plasmid was not properly transfecting the 
MCF10A cells. 
pmaxGFP pSUPER.gfp+neo.neg
experiments will use small molecule RNA mimics to overexpress ts-2 and ts-112 fol-
lowed by the same phenotypic assays a the inhibition experiments.  
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Discussion Overexpression  
 The purpose of overexpressing ts-2 and ts-112 in the normal-like mammary MCF10-
CA cell line was to validate the results of the inhibition experiments. The MCF10A cell 
line has low expression of ts-2 and ts-112 while the aggressive MCF10CA1a breast can-
cer cell line exhibits high expression of ts-2 and ts-112. tsRNA and the negative control 
utilized custom purchased plasmids from OligoEngine (pSUPER.GFP+neo.neg, pSU-
PER.GFP+neo.ts2 or pSUPER.GFP.ts112). Plasmids were first transformed into the E.-
coli. STBL3 cells, and then transfected into the normal-like mammary MCF10A cell line. 
Plasmids contained GFP to verify the transfection with fluorescence and utilized an H1 
promoter to drive polymerase III to overexpress ts-2 and ts-112. Our hypothesis was that 
overexpression of ts-2 and ts-112 in the normal-like MCF10A cell line would result in the 
opposite effects as inhibiting the tsRNAs in the aggressive MCF10CA1a cell line. If the 
overexpression experiments showed reciprocal results the results of the inhibition exper-
iments would be validated. Both ts-2 and  ts-112 appears to have mechanistic role in the 
following hallmarks of cancer: replicative immortality, cell proliferation and evasion of 
apoptosis. 
 Following transfection of ts-2 and ts-112 plasmids into the normal-like mammary 
MCF10A cell line there was no sign of fluorescence in the cells. We then decided to do a 
quality control check of the purchased plasmids from OligoEngine after multiple RT-
qPCRs that indicated there was no sign of GFP mRNA. After no indication of transfec-
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tion either visually or by RT-qPCR we hypothesized that there was a problem with either 
the methods of the transformation or transfection of the plasmids.  
 To test our hypothesis we took the negative control plasmid 
(pSUPER.GFP+neo.neg) directly from the stock OligoEngine plasmids and transfected it 
into the MCF10A cell line in a 10mL petri dish. As a positive control, Pmax GFP that was 
available in lab was transfected into the normal-like breast epithelial  MCF10A cell line. 
The result of this experiment showed that the positive control Pmax GFP was able to suc-
cessfully transfect the cell line using the previously used methods for our phenotypic as-
says. This assay showed that the issue with the previous experiments was not in the 
method of the transfection but with the plasmids supplied from OligoEngine.  
 The purchased negative control plasmid (pSUPER.GFP+neo.neg) again did not 
show visual fluorescence or RT-qPCR GFP mRNA (Figure 2.6). We followed up with the 
company multiple times and have not yet had a response. Since the purchased Oligo-
Engine plasmids did not work properly we were unable to continue with the phenotypic 
assays.  
 If the plasmids had worked correctly we hypothesize that they would have the op-
posite result of the inhibition experiments. Inhibition of ts-2 and ts-112 resulted in no 
change in cell growth when ts-2 was inhibited and a decrease in cell growth of ts-112. 
The growth curve following ts-2 and ts-112 overexpressions should then result in no 
change in ts-2 cell growth and an increase in MCF10A cell growth following overexpres-
sion of ts-112. The cell growth assay will validate that ts-2 may not have a role in cell 
growth and that ts-112 will play a mechanistic role in the hallmarks: unlimited prolifera-
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tion and replicative immortality. Using the growth curve to analyze doubling time after 
ts-2 and ts-112 inhibition resulted in an increase in ts-2 doubling time and no change in 
ts-112 doubling time; therefore, overexpression should result in no change when analyz-
ing ts-2 doubling time and ts-112 should result in a decrease in doubling time. The over-
expression doubling time will validate that ts-2 has a regulatory effect in the hallmarks: 
replicative immortality and unlimited proliferation.  
 Analyzing cell death using a trypan blue exclusion assay following inhibition of 
ts-2 and ts-112 resulted in an increase in cell death in both tsRNAs. Overexpression of ts-
2 and ts-112 should then also result in a decrease in cell death. This assay will validate 
whether both tsRNAs have an effect on the hallmark of evasion of apoptosis. To analyze 
cell motility and the hallmark of breast cancer of metastases, overexpression of ts-2 and 
ts-112 would show no change in motility. The results of inhibiting ts-2 and ts-112 in the 
MCF10CA1a cell line resulted in no change when ts-2 was inhibited and a statically sig-
nificant increase in S phase and decrease in G1 phase when ts-112 was inhibited. Over-
expression of ts-2 and ts-112 could lead to a decrease in S phase and increase in G1 
phase. 
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Part C: Methods  
Methods Inhibition  
Cell Culture 
 All tsRNA inhibition experiments were performed in the MCF10CA1a aggressive 
breast cancer cell line, a Stein/Lian lab stock. Cells were maintained in tissue culture 
treated-plastic, uncoated sterile petri dishes with an appropriate volume of DMEM/F12 
50/50 L-glutmaine media (Gibco) that contained 5% horse serum (Gibco) and 1% peni-
cillin streptomycin (Gibco). Cells were passaged every 2-3 days or when plates were 
75-100% confluent and were maintained between 14-30 passages.  
 Cells were passaged with 0.25% Trypsin-EDTA (Thermo Fisher Scientific). Me-
dia was changed between every passage. MCF10CA1a aggressive breast cancer cells 
were maintained in a 37°C humidified incubator at 5% CO2. 
tsRNA Inhibition 
 MCA10CA1a cells were transfected with a 1:5 ratio of lipofectamine 2000 to 
miRIDIAN hairpin inhibitors (Dharmacon) designed against either ts-2 or ts-112 in Opti-
MEM. Negative controls used an inhibitor against cel-mir-39-3p, a C. elegans miRNA 
not expressed by mammalian cells that was tagged with a fluorescent dye, Dy546 to al-
low for conformation of transfection. Mock samples used additional nuclease free water 
as a replacement for the inhibitors given. Final transfection concentration of the custom 
Dharmacon miRIDIAN inhibitors was 50nM. Transfection was performed twelve hours 
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prior to phenotypic assays: growth curve, doubling time, cell cycle and scratch wound 
healing.  
Forward qPCR primers for short RNA using a universal reverse primer
Growth Curve Analysis Following tsRNA Inhibition   
 The aggressive breast cancer cell line, MCF10CA1a, was initially transfected with 
custom hairpin inhibitors (Dharmacon) against ts-2, ts-112 or negative control. A mock 
sample using nuclease free water was also transfected. All four samples were plated in 
three replicates at  2.5x10^4 cells per well in 2mL uncoated six well plates in complete 
media twelve hours following transfection.  At 24hr and 48hr after plating, cells were 
trypsonised and stained with 0.4% Trypan Blue Solution (Thermo Fisher Scientific) 
which is an azo dye that selectively colors dead cells due to their porous membranes. To-
tal, viable, and dead cells were measured on a Countess (v1 or v2) automated cell counter 
(Invitrogen). Cell count and time point data were entered into GraphPad Prism v7 and 







Table 2.2:  Forward qPCR for short RNA using a universal reverse primer. Forward 
primers used for all small RNA RT-qPCR. 
Doubling Time Analysis Following tsRNA Inhibition  
 The doubling time following ts-2 and ts-112 inhibition using custom inhibitors 
(Dharmacon) in the aggressive breast cancer cell line; MCF10CA1a, was calculated using 
the growth curve in the previous assay on graphed Prism. The growth curve was set up as 
an exponential curve on an XY data table using the nonlinear regression analysis. The 
time represented X axis and the cell number represented the Y axis. The model line was 
accompanied by the equation (Y=Y0*exp(k*x). Y0 is representative of the Y value when 
X was at zero, K is the constant inverse rate of time passing, X (tau) is the constant of 
time (reciprocal of K) and finally the doubling time is the time units of the X axis. The 
doubling time was calculated by the following equation: (ln(2)/K). The doubling times 
were then turned into a bar graph with error bars that are representative of the standard 
error of the mean. 
Trypan Blue Exclusion Following Inhibition  
 The aggressive breast cancer cell line, MCF10CA1a, was initially transfected with 
custom ts-2, ts-112, and negative control hairpin inhibitors (Dharmacon) and then plated 
in three replicates twelve hours following transfection at 25,000 cells per well in 2mL 
complete media six well plates. A mock control was also plated at the same density and 
time. Cells were raised from the plate using 0.25% Trypsin-EDTA (Thermo Fisher Scien-
tific) at two time points; 36 and 60 hours following transfection. Transfected cells were 
stained with 0.4% Trypan Blue Solution (Thermo Fisher Scientific) and then counted on 
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Countess (v1 or v2) an automated cell counter (Invitrogen). Cell death was recorded and 
data points were turned into a bar graph on Prism.  
RNA Isolation  
 MCF10A and MCF10CA1a cells were harvested after  being washed with 1x 
phosphate-buffered saline (PBS) and then having 0.7-1mL QIAzol added to each sample. 
Samples in both six well and 10mL plates received the same amount of QIAzol. After 
harvesting, samples were either frozen in a -80°C freezer or used immediately for RNA 
isolation.  
 Cells that were frozen were thawed on ice. To harvest the cells, plates were 
scraped using a plastic cell scraped into 1.5mL Eppendorf tubes, vortexed thoroughly to 
completely lyse the cells and then incubated at room temperature for five minutes. After 
samples were lysed, 140-200uL of chloroform, dependent on lysate volume was added to 
each sample and were incubated again for three minutes at room temperature. The upper 
aqueous solution was transformed into a new 1.5mL Eppindorf tube. RNA was isolated 
using the miRNeasy Mini Kit (QIAGEN). Following the manufacturers protocol RNA 
was eluted in 30uL of RNAse free water. A mock sample for each experiment was also 
prepared using the same protocol that only contained excess water rather than inhibited 
tsRNA. RNA was stored in a -80°C freezer.  
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cDNA synthesis for RT-qPCR  
 Following RNA isolation, complementary deoxyribonucleic acid (cDNA) was 
synthesized using miScript II RT Kit (QIAGEN). Samples of RNA were diluted with nu-
clease free water to 1000ng of RNA based on nano-drop concentrations. After dilution of 
each sample, (mock, ts-2 and ts-112 inhibited RNA) 3uL from each stock sample was 
pipetted into an additional Eppendorf tube labeled 
 -RT pool to act as a negative control for the experiment. An additional 1uL of nuclease 
free water was added to the -RT pool for accurate concentration.  
 A master mix was created in a fifth Eppendorf tube that contained enough reagent 
for the mock, inhibited ts-2 or ts-112 samples. Each of these samples received 4uL of 5x 
miScript HiSpec Buffer, 2uL 10x miScript Nucleics Mix and 2uL nuclease free water. Af-
ter the master mix had been distributed to each of the three samples 2uL of miScript re-
verse transcriptase Mix was added to the mock, inhibited ts-2 or ts-112 samples. The 
mock, inhibited ts-2 and ts-112 samples contained a total of 10uL of reagents.  
 The -RT pool also contained 4uL of 5x miScript HiSpec Buffer, 2uL miScript Nu-
cleics Mix and 2uL of nuclease free water. The -RT pool did not receive 2uL of the miS-
cript reverse transcriptase Mix and instead was given an additional 2uL of nuclease free 
water.  
 After each cDNA mix was made (mock, -RT pool, inhibited ts-2 and inhibited 
ts-112) each sample was gently spun and then put into the thermo-cycler for 60 minutes 
at 37°C, 5 minutes at 95°C and held at 4°C. Samples were then stored at -20°C.  
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RT-qPCR Small RNA techniques  
 Previously synthesized cDNA of -RT pool, mock and inhibited ts-2 or ts-112 in 
the aggressive breast cancer cell line MCF10CA1a was taken out of the -20°C freezer and 
thawed on ice. Real time quantitative polymerase chain reaction (RT-qPCR) was used to 
assure cells were properly transfected with the custom inhibitors (Dharmacon). RT-qPCR 
was performed using small RNA protocol.  
 A master mix was created for each reaction that contained 2uL of Universal re-
verse primer and 4uL nuclease free water. 2uL of miRNA-specific forward primer (60s 
RPL13a, ts, ts-112) was added to the 6uL of Universal Primer master mix. 60s RPL13a 
was used as the housekeeping gene. For each each well in the 96 well plate that required 
that specific miRNA-specific forward primer received 8uL total.  
 For the previously made cDNA (-RT pool, mock, inhibited ts-2 or ts-112) 10x 2x 
QuaniTect SYBR Green PCR Master Mix, 0.2uL cDNA and 1.8uL of nuclease free water 
was added to each appropriate well for a total of 12uL.  
 Each well contained a total 20uL of reagents for each reaction in the 96 well plate. 
After filling and placing a translucent protectant sticker on the top of the plate it was cen-
trifuged for 30-60 seconds. RT-qPCR plates was run on ViiA7 RT-qPCR machine at the 
following times: 95°C for 15 minutes with 40 cycles of 94°C for 15 seconds, 55°C for 30 
seconds and 70°C for 30 seconds. A melt curve analysis was also completed. 
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Cell Cycle Analysis Using Flow Cytometry  
 MCF10CA1a cells were  plated at 1x106 in four different 10mL plastic, uncoated 
plates. The three plates were labeled negative control, inhibited ts-2 and inhibited ts-112. 
The negative control was an inhibitor against cel-miR-39-3p, a C. elegans miRNA not 
expressed by mammalian cells that was tagged with a fluorescent dye, Dy546 to allow for 
conformation of transfection. Three hours after transfection cells were washed and placed 
into 10mL complete media.  
 Twenty four hours following transfection cells were harvested with 0.25% 
trypsin-EDTA (Thermo Fischer Scientific) and fixed dropwise with 70% ice-cold ethanol 
and stored at 4°C.  
 For cell cycle analysis cells were rinsed twice upon removal from 4°C. The first 
wash was performed with 1xPBS and the second with propidium iodide RNase staining 
buffer (BD Pharmingen). The cells were spun for 10 minutes at 1,000 revolutions per 
minute (RPM) at 4°C and the supernatant was decanted. Each sample was then resus-
pended in 2mL 1x PBS and filtered through a cell-strainer capped tube (5mL Falcon 
Polystyrene Round-Bottom) and then spun again for 10 minutes at 1,000 RPM at 4°C. 
The supernatant was again decanted. An unlabeled control sample was made of a 1:1:1:1 
ratio of each of the other samples to make 100ml and was treated the same as the other 
samples. The mock sample was then rinsed with 1x PBS and the inhibited samples were 
rinsed with 1mL PI/RNase Staining Buffer (BD Pharmingen) and then spun again for 10 
minutes at 1,000 RPM at 4°C. The supernatant was decanted again.The mock sample was 
resuspended in 0.5mL 1x PBS and the other four samples (mock, -CTRL, inhibited ts-2 
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and inhibited ts-112) were resuspended with PI/RNase Staining Buffer (BD Pharmingen). 
The unlabeled control sample was not stained using the PI/RNase Staingin Buffer (BD 
Pharmingen) and was used as a blank other samples.  All five samples were incubated for 
fifteen minutes at room temperature and then were brought to BD LSR II flow cytometry 
within one hour of experiment completion. Analysis of samples was performed by Dr. 
Roxana Del-Rio in the UVM cancer center Flow Cytometry Core.   
 The analysis resulted in a raw peak for each of the four samples (mock, -CTRL, 
inhibited ts-2 and inhibited ts-112). From these raw peaks we were able to get a numeri-
cal value for the space under each of the peaks and analyzed using ModFit software. The 
first peak was representative of G1 and the second peak was representative of G2/M with 
S phase being the valley in between them. By taking the overall amount of cells that were 
being analyzed and the amount of cells found under each peak we were able to conclude 
what percent of cells were in each phase of the cell cycle. This data was collected and put 
into Prism which was then put into a bar graph. The bar graph compared the samples to 
the mock sample using a T-test. The error bars of the bar graph are representative of the 
standard error of the mean. The sample size of this experiment was 3.  
RT-qPCR of Candidate mRNA Checkpoint Genes  
 Following the analysis of cell cycle using flow cytometry a candidate approach 
was taken to analyze specific check point genes (ATR, CDKN1A (p21), CCNA2, CC-
NE1, BCL-2, tP53 (p53), SRSF3, CHEK1 and CHEK2) using a RT-qPCR assay. Each 
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mRNA primer came as a forward and reverse primer so they had to be appropriately 
mixed depending on their concentration with nuclease free water.  
 A master mix was made for each previously made cDNA for mRNA analysis (-RT 
pool, mock, inhibition of ts-2 and ts-112) in an Eppendorf tube. For each tube 0.2uL of 
appropriate cDNA, 1.8uL nuclease free water and 10uL 2x iTaq Universal SYBR Green 
Supermix was added for each reaction. After the master mix was made each well received 
12uL of this solution per reaction.  
 For the mRNA-specific primer (ATR, CDKN1A (p21), CCNA2, CCNE1, BCL-2, 
tP53 (p53), SRSF3, CHEK1 and CHEK2) a master mix was first created.  
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RNA Gene Name Species Type sequence Source



























































































Forward and Reverse Primers for long RNA for RT-qPCR of 
candidate cell cycle analysis genes. 
 Each mRNA primer contained 7.2uL nuclease free water and 10uM mRNA spe-
cific forward/reverse primer. Each well received 8uL of the mRNA primer master mix per 
well.   
 Each well in the 96 well plate had a total of 20uL of solution per reaction. The 
finished plate had a protectant translucent sticker placed on the top and was centrifuged 
for 10 seconds and then placed into the ViiA7 qPCR machine on the fast setting. Each 
plate was run at 95°C for 30 seconds followed by 40 cycles of 95°C for 3 seconds and 










































Table 2.3: Forward and Reverse Primers for long RNA for RT-qPCR of candidate cell 
cycle analysis genes. 
Scratch Assay  
 MCF01CA1a cells were seeded in triplicates at 1.5x106 per well in uncoated, 
plastic trans-well plate and labeled -CTRL, mock, inhibited ts-2 or inhibited ts-112. 
Transfected aggressive MCF10CA1a breast cancer cells were scratched using a p200 
pipette tip. Then confluent cell plates were marked using a marker on the bottom of each 
well so that each scratch overlapped onto two drawn lines. MCF10CA1a cells were then 
washed with PBS and given reduced serum media. Images of the cells were taken at 4x 
and 10x at each crossing of the marker and the wound in the same location every eight 
hours for 24 hours. There was a total of twelve images per well. These initial experiments 
found that the wounds were closing too quickly and so the methods was then optimized 
to analyze the cells every fours for sixteen hours.  
 Raw images of wound healing over time for each of the five timepoints was then 
put into the MiToBo plugin for ImageJ. This program took the raw images of each sam-
ple (mock, -CTRL and inhibition of ts-2 or ts-112) and turned them into binary images 
that could then be placed a numerical value for either the amount the wound was healed, 
open or total area in pixels. These numerical values were placed into an excel sheet for 
each of the twelve images per well per sample at each time point. The percent open was 
calculated by dividing the total pixels of open space divided by the initial amount of open 
space at time point 0. The inverse of the area open; area healed, was calculated by taking 
the initial amount of area healed at time point zero and dividing it by the pixels at each 
time point. This then resulted in percent open and percent healed. These results were put 
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into prism where they were averaged and placed into graphs to better visualize the 
amount each wound was open an each wound healed.  
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Overexpression Methods 
 The MCF10A cell line stock plates were grown in untreated, plastic 10mL petri 
dishes. To maintain the normal-like breast epithelial MCF10A cell line media was made 
from DMEM/F12 50/50 with L-glutamine (Gibco), 5% horse serum (Gibco), 1% peni-
cillin, 10ug/mL human insulin, 20ng/mL human epidermal growth factor, 100ng/mL 
cholera toxin, 0.5ug/mL hydrocortisone and 1% L-glutamine. Media was changed every 
1 to 2 days and cells were passaged every 3 to 4 days depending on confluencey of the 
plate. Cells were stored in a 37°C humidified incubator at 5% CO2. All phenotypic assays 
were done using a transfected plasmid from OligoEngine; pSuper.gfp/neo that had a pro-
moter region for green fluorescent protein (GFP) to ensure there was proper transfection. 
Three different custom plasmids were purchased: pSUPER.GFP+neo.neg, pSU-
PER.GFP+neo.ts2 and pSUPER.GFP.ts112. Each plasmid contained an H1 promoter re-
gion for polymerase III transcription to over express ts-2 and ts-112. Plasmids also con-
tained a region for ampicillin resistance which allowed only transfected cells to grow in 





 Following overexpression of ts-2 and ts-112 a growth curve, trypan blue exclu-
sion, scratch assay and cell cycle analysis were planned to be the reciprocal experiments 
of the inhibition assays.  
Bacterial Transformation  
 The bacterial transformation consisted of three plasmid samples: 
pSUPER.GFP+neo.neg, pSUPER.GFP+neo.ts2 and pSUPER.GFP.ts112. Three stock 
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Custom OligoEngine pSuper.gfp/neo Plasmid 
Figure 2.5 Custom OligoEngine pSuper.gfp.neo plasmid for overexpression of 
ts-2 and ts-112. This custom plasmid was designed to overexpress ts-2 and 
ts-112 in the MCF10a normal-like breast cell line. The section highlighted in 
the blue box is the H1 promotor region that is where polymerase III binds to 
translate the plasmid. The green box represents where the green fluorescent 
protein that is driven by a PKG promoter is located.
100uL of STBL3 bacterial, E.Coli tubes were thawed on ice. 2uL of each purchased 
plasmid was added to each tube once thawed. Samples were then incubated on ice for 
thirty minutes. They were then incubated at 42°C for 90 seconds and then another two 
minutes on ice.  
 A stock amount of Luria-Bertani broth (LB Broth) was made during the initial 
bacterial transformation for future experiments. To make the broth half a liter of Milli-Q 
was added to a 5L graduated cylinder. 10g of Tryptone, 5g of yeast extract and 10g of 
Sodium Chloride were added to the cylinder and mixed using a stirring rod. When the 
particles had dissolved the cylinder was filled to 1L to create a total of 1L of LB broth. 
Each time LB broth was added to a sample it was done next to a flame to maintain steril-
ization.  
 Each of the incubated samples (mock, negative control, overexpressed ts-2 and 
overexpressed ts-112) received 500uL of LB broth and was incubated for one hour at 
37°C. Following incubation 150uL of ampicillin (Gibco) and 150uL of LB broth was 
added to each of the samples. Samples were then incubated overnight in a automated 
shaker at 37°C to allow cells to grow.  
DNA Isolation  
 Following bacterial transformation, the contents of the Erlenmeyer flasks were 
poured into 500mL plastic centrifuging bottles that were labeled for each of the four 
samples (-CTRL, mock, over expression of ts-2 and over expression of ts-112). All four 
samples were then spun for fifteen minutes at 6,000 g’s. DNA isolation followed the Zy-
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moPURE II Plasmid Maxi Kit (ZYMO Research) manufacturing protocol. This protocol 
entailed lysing the proteins of the cells and filtering out the transfected DNA following 
the vacuum protocol. DNA was eluted with 400uL of ZymoPURE Elution Buffer 
(ZYMO Research). After the elution of DNA a nano-drop was done to measure the quan-
tity and quality of the obtained DNA of each sample. Each sample was stored at -20°C.  
Transfection of Transformed DNA into MCF10A Cell Line  
 Normal-like breast cell line, MCF10A, was plated in three 10mL plastic uncoated 
plates labeled overexpressed ts-2, overexpressed ts-112 and negative control. Transfec-
tion began with three different 1.5mL Eppindorf tubes that were labeled for each of the 
controls. 5uL of the extracted DNA with transformed plasmid and 750uL of opti-MEM 
was added to each labeled tube. A master mix of 87.5uL of Lipofectamine 2000 and 
2.625mL of opti-MEM was mixed and sat at room temperature for five minutes. From 
this master mix 750uL was added to each of the sample tubes that contained the bacterial-
ly transformed DNA and opti-MEM. Samples then rested at room temperature for 20-30 
minutes. 
 Each plate was transfected with 25uL lipofectamine and 5uL of either pSU-
PER.GFP+neo.neg, pSUPER.GFP+neo.ts2 or pSUPER.GFP.ts112 DNA that had previ-
ously been extracted from the STBL3 E. Coli cell line and 1.125mL of opti-MEM.  
 Plates were then washed once with PBS and 3.5mL of complete media was added 
to each plate. Each sample was than pipetted in totality into each plate and the time of 
day was recorded. Three hours following transfection the plates were washed once with 
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PBS and 10mL of complete media was added to each of the plates and the time was 
recorded. Transfected plates were stored in a 37°C incubator at 5% CO2.  
RNA Isolation  
 Following transfection of a negative control, overexpressed ts-2 or overexpressed 
ts-112,  aggressive breast cancer cells; MCF10Ca cells were harvested after  being 
washed with 1x phosphate-buffered saline (PBS) and then having 0.7-1mL QIAzol added 
to each sample. Samples in both six well and 10mL plates received the same amount of 
QIAzol. After harvesting, transfected MCF10CA1a cells could either be frozen in a 
-80°C freezer or used immediately for RNA isolation following the addition of 1mL of 
QIAzol was added to each well/plate.  
 Cells that were frozen were thawed on ice. To harvest the cells plates were 
scraped into 1.5mL Eppindorf tubes, vortexed thoroughly to completely lyse the cells and 
then incubated at room temperature for five minutes. After samples were lysed, 140uL of 
chloroform was added to each sample and were incubated again for three minutes at room 
temperature. The upper aqueous solution was pipetted into a new 1.5mL Eppindorf tube. 
RNA was isolated using the miRNeasy Mini Kit (QIAGEN). A mock sample for each ex-
periment was also prepared using the same protocol that only contained excess water 
rather than inhibited tsRNA. RNA was stored in a -80°C freezer. 
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cDNA Synthesis for RT-qPCR 
 Following RNA isolation, cDNA was synthesized using miScript II RT Kit (QIA-
GEN). Samples of RNA were diluted with nuclease free water to 1000ng of RNA based 
on nano-drop concentrations. After dilution of each sample, (mock, ts-2 and ts-112 over-
expressed RNA) 3uL from each stock sample was pipetted into an additional Eppendorf 
tube labeled -RT pool to act as a negative control for the experiment. An additional 1uL 
of nuclease free water was added to the -RT pool for accurate concentration.  
 A master mix was created in a fifth Eppendorf tube that contained enough reagent 
for the mock, overexpressed ts-2 or ts-112 samples. Each of these samples received 4uL 
of 5x miScript HiSpec Buffer, 2uL 10x miScript Nucleics Mix and 2uL nuclease free wa-
ter. After the master mix had been distributed to each of the three samples 2uL of miS-
cript reverse transcriptase Mix was added to the mock, overexpressed ts-2 or ts-112 sam-
ples. The mock, overexpressed ts-2 and ts-112 samples contained a total of 10uL of 
reagents.  
 The -RT pool also contained 4uL of 5x miScript HiSpec Buffer, 2uL miScript Nu-
cleics Mix and 2uL of nuclease free water. The -RT pool did not receive 2uL of the miS-
cript reverse transcriptase Mix and instead was given an additional 2uL of nuclease free 
water. After each cDNA mix was made (mock, -RT pool, overexpressed ts-2 and overex-
pressed ts-112) each sample was gently spun and then put into the thermo-cycler for 60 
minutes at 37°C, 5 minutes at 95°C and held at 4°C. Samples were then stored at -20°C. 
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Small RNA RT-qPCR to Assure Transfection Following Overexpression  
 Previously synthesized cDNA of -RT pool, mock and overexpressed ts-2 or ts-112 
in the aggressive breast cancer cell line; MCF10Ca was taken out of the -20°C freezer 
and thawed on ice.  RT-qPCR was used to assure cells were properly transfected with the 
custom plasmids (OligoEngine). RT-qPCR was performed using small RNA protocol.  
 A master mix was created for each reaction that contained 2uL of Universal re-
verse primer and 4uL nuclease free water. 2uL of miRNA-specific forward primer (60s 
RPL13a, ts2 and ts-112) was added to the 6uL of Universal Primer master mix. 60s 
RPL13a was used as the housekeeping gene. For each each well in the 96 well plate that 
required that specific miRNA-specific forward primer received 8uL total. For the previ-
ously made cDNA (-RT pool, mock, overexpressed ts-2 or ts-112) 2x QuaniTect SYBR 
Green PCR Master Mix, 0.2uL cDNA and 1.8uL of nuclease free water was added to 
each appropriate well for a total of 12uL per well.  
 Within the 96 well plate each reaction contained a total 20uL of reagents. After 
filling and placing a translucent protectant sticker on the top of the plate it was cen-
trifuged for 10 seconds. The qPCR plate was run on ViiA7 RT-qPCR machine at the fol-
lowing times: 95°C for 15 minutes with 40 cycles of 94°C for 15 seconds, 55°C for 30 
seconds and 70°C for 30 seconds. A melt curve analysis was also completed. 
Quality Check of OligoEngine Primer  
 A transfection was performed using the same methods as previously mentioned of 
the three OligoEngine pSUPER plasmids but instead of growing the plasmids up in the 
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STBL3 bacterial cell line, plasmids were taken directly from the stock bottles we re-
ceived from the company. We compared the OligoEngine plasmid against a positive con-
trol (pmaxGFP) in two 10mL plates and then assessed each plate 24 hours post transfec-
tion for fluorescence. We took images of transfected cells at 4x using brightfield and un-
der fluorescent light. 
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Chapter 3 Discussion and Future Directions 
 There are ten hallmarks of cancer that define the characteristics that cancers can 
adapt in order to survive [35]. The hallmarks associated with breast cancer are sustaining 
proliferative signaling, activating invasion, metastasis, evading immune destruction, 
deregulating cellular energetics, genome instability, and mutations in genetics [35]. 
Breast cancer is the most diagnosed cancer in women in the world. In the United States 
there is a one in eight chance (12.38%) of a woman being diagnosed with breast cancer in 
her lifetime [6]. Compared to earlier stages of breast cancer (stages I-III) metastatic 
breast cancer (stage IV) continues to have low five year survival rates (20%) even with 
new advances in medicine and diagnostic tools [23]. For these reasons there is a need for 
further study into the cellular and molecular mechanisms of metastatic breast cancer.  
 Previous research has indicated that tsRNAs have mechanistic function in other 
cancers such as lung cancer [73]. ts-2 and ts-112 may have elevated expression in in-
creasingly aggressive breast cancer cell lines and in an embryonic stem cell line, H9 hES. 
In order to bridge the gap between the low survival rates of metastatic breast cancer 
(stage IV) and the possible mechanistic involvement of ts-2 and ts-112 we decided to ex-
plore the function of these ts-RNAs in metastatic breast cancer. 
 The first aim of the project was to inhibit ts-2 and ts-112 using custom Dharma-
con miRIDIAN hairpin inhibitors in the aggressive breast cancer cell line, MCF10CA1a. 
We hypothesized that the inhibition of ts-2 and ts-112 would result in a decrease in cancer 
characteristics. In this project we explored the role of ts-2 and ts-112 in following four 
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hallmarks of breast cancer: unlimited proliferation, evasion of apoptosis, invasion and 
metastasis and replicative immortality.  
 In order to analyze the role that ts-2 and ts-112 play in the hallmarks of cancer 
related to metastatic breast cancer we looked at viable cell growth, doubling time, cell 
death, scratch/wound healing and cell cycle. Inhibition of ts-2 and ts-112 resulted in no 
change in cell growth for ts-2 and a decrease in cell growth for ts-112. Using the growth 
curve to analyze doubling time after ts-2 and ts-112 inhibition resulted in an increase in 
ts-2 doubling time and no change in ts-112 doubling time. This assay showed that ts-2 
may have a regulatory effect in the following hallmarks of breast cancer: replicative im-
mortality and unlimited proliferation.  
 To analyze cell death a trypan blue exclusion assay was done following inhibition 
of ts-2 and ts-112. The result of the trypan blue exclusion showed that both ts-2 and 
ts-112 inhibition resulted in an increase in cell death in the aggressive MCF10CA1a cell 
line. This assay suggests that both tsRNAs may have a regulatory role in the hallmark of 
breast cancer, evasion of apoptosis. To analyze cell motility and the hallmark of breast 
cancer, metastasis, inhibition of ts-2 and ts-112 showed no change in motility; therefore, 
ts-2 and ts-112 may not have a molecular role in the metastasis of aggressive breast can-
cer.  
 Finally, because of the apparent regulatory role that ts-2 and ts-112 play in unlim-
ited proliferation and replicative immortality, cell cycle was analyzed using flow cytome-
try. The result of this assay was that the inhibition of ts-112 showed a statistically signifi-
cant increase of cells in S phase and decrease in G1 phase. This assay along with de-
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creased cell growth validate that ts-112 does have a role in the hallmarks of breast cancer: 
replicative immortality and unlimited proliferation. To follow up our statistically signifi-
cant finding from flow cytometry, we then took a candidate approach and evaluated if ts-
2 and ts-112 had any biological association with nine cell cycle and breast cancer associ-
ated genes (ATR, CDKN1A (p21), CCNA2, CCNE1, BCL-2, tP53 (p53), SRSF3, 
CHEK1 and CHEK2). The result of these RT-qPCRs showed that there was no connec-
tion between ts-2, ts-112 and the selected candidate genes. In order to validate our find-
ings, the overexpression component of the project will need to be completed using tsRNA 
mimics followed by the same phenotypic assays.     
 Future directions of the inhibition of ts-2 and ts-112 are to continue assays to ana-
lyze tsRNA functions in the hallmarks of cancer and MCF10CA1a. These assays include 
western blots, assessing invasion using transwell plates, TUNEL assays and microchip 
arrays.   
 The second aim of our project was to overexpress ts-2 and ts-112 using custom 
plasmids from OligoEngine in the normal-like MCF10A cell line. The goal of the second 
half of this project was to validate the inhibition experiments. For that reason, our hy-
pothesis was that the overexpression of ts-2 and ts-112 would result in an increase in can-
cer characteristics. After many failed transfections and validation of failed transfection 
using RT-qPCR, it was apparent that we did not receive functional plasmids from Oligo-
Engine. In the future, ts-2 and ts-112 will be overexpressed using mimics followed by the 
assays that were completed in the inhibition experiments.  
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 Long term goals of this project are to characterize the function of ts-2 and ts-112 
in the aggressive breast cancer cell line, MCF10CA1a in vitro. When ts-2 and ts-112 have 
a defined characterization, in vivo assays in mice using xenographed cell lines could be 
done to further our understanding of the cellular mechanisms and to validate the complet-
ed in vitro assays. 
 In order to fill the prognosis gap between earlier stages of breast cancer (stage I-
III) and metastatic breast cancer (stage IV), there needs to be further research in the cellu-
lar and molecular happenings leading to metastatic breast cancer. The future research of 
ts-2 and ts-112 may bridge this gap in knowledge by not only helping us understand the 
function of these two particular tsRNAs, all tsRNAs but also in metastatic breast cancer. 
In the far future ts-2 and ts-112 could be used as a way to differentiate the aggressiveness 
of a breast cancer, and allow for more accurate treatments. tsRNA function is still largely 
unknown and only a few publications have been addressed on their function. Continued 
research could lead us to further understanding of not only breast cancer but perhaps all 
cancers.
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